

# Index — Volume 44 — 1999

## Author Index

### A

- Abbass A** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)
- Adam KS** *see* West ML (578)
- Addington D** *see* Canadian Psychiatric Association Scientific and Research Council (1049); Dickson RA (909); Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Addington D, Addington J, Robinson G**  
Attributional style and depression in schizophrenia 697
- Addington J** *see* Addington D (697); el-Guebaly N (264)
- Aghababian V** *see* Lançon C (893)
- Agro K** *see* Goeree R (455; 464)
- Alda M**  
Shulman KJ, Tohen M, Kutcher SP, editors. *Mood disorders across the life span*. [book review] 90  
Skolnick P, editor. *Antidepressants: new pharmacological strategies*. [book review] 281
- Al Jeshi A**  
Moclobemide response in obsessive-compulsive disorder [letter] 285
- Allain S** *see* Haggarty JM (711)
- Anand HS**  
Olanzapine in an intensive care unit [letter] 397
- Ananth J**  
Is olanzapine a mood stabilizer? [letter] 927
- Ancill RJ** *see* Kiraly SJ (92)
- Anisman H** *see* Ravindran AV (805)
- Antony MM** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)
- Arana GW** *see* Labbate LA (488)
- Arboleda-Flórez J** *see* Quan H (762)
- Armstrong H**  
Penfold PS. *Sexual abuse by health care professionals: a personal search for meaning and healing*. [book review] 918
- Armstrong S** *see* el-Guebaly N (264)
- Asghar SJ, Chue PS, Coupland NJ, Tibbo P**  
Polyglandular autoimmune syndrome type II and paranoid schizophrenia with obsessive-compulsive disorder [letter] 391
- Auquier P** *see* Lançon C (893)
- Azim HF** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)

### B

- Baigent L, Ostbye T, Fernando MLD**  
Feasibility of client reports to measure treatment outcome in schizophrenia [letter] 94
- Bain J** *see* Langevin R (775)
- Barbieri NB**  
Psychoanalytic contributions to the study of gender issues 72
- Barnard-Thompson K, Lechner P**  
Psychiatric residents' views on their training and experience regarding issues related to child abuse (769)

- Barnsley RH** *see* Thompson AH (82)
- Bartley S** *see* Lam RW (158)
- Bartoli JL** *see* Grignon S (91)
- Bassett AS** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Bassiri D** *see* Grignon S (91)
- Bastos O** *see* Petribú K (93)
- Bean G** *see* Zhang-Wong J (164)
- Beauchamp G** *see* Gagnon A (606)
- Beauchemin M-A** *see* Lapierre O (188)
- Beaudoin CM, Cox BJ**  
Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire 483
- Behchuk W** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Chair (3S); Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)
- Beck C, Silverstone P, Glor K, Dunn J**  
Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey 680
- Beiser M** *see* Zhang-Wong J (164)
- Bell RC** *see* Mai FM (478)
- Benazzi F**  
Bipolar II and unipolar atypical depression [letter] 1050  
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder [letter] 607  
Re: selective serotonin reuptake inhibitor discontinuation syndrome: putative mechanisms and prevention strategies [letter] 95  
[response] 287; *see* Markowitz JS (286)
- Benazzi F, Rossi E**  
Mania and donepezil [letter] 506
- Bennett KJ** *see* Lipman EL (604)
- Bennett VL** *see* Li X-M (605)
- Benoit F, Lesage AD**  
L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé 781
- Bernard D** *see* Lançon C (893)
- Bernier J** *see* Roy M (283)
- Bertolote JM** *see* Taborda JGV (180)
- Bird DC** *see* Dursun SM (701)
- Black DN** *see* Roy M (671)
- Blackhouse G** *see* Goeree R (455; 464)
- Blake P** *see* Cooke RG (379)
- Bland RC**  
Precursors to schizophrenia [editorial] 325
- Blank P** *see* Taborda JGV (180)
- Blin O**  
A comparative review of new antipsychotics 235
- Boisjoly H** *see* Stip E (503)
- Boivin M** *see* Trudeau M-H (583)
- Booker L** *see* Jadad AR (1025)
- Borgeat F** *see* O'Connor K (64)
- Boulay LJ** *see* Labelle A (190; 887)
- Boulter M, Steiner M**  
Stewart DE, Erlick Robinson G, editors. *A clinician's guide to menopause*. [book review] 186
- Bowman ML**  
Individual differences in posttraumatic distress: problems with the DSM-IV model 21

# Index — Volume 44 — 1999

## Author Index

### A

- Abbass A** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)
- Adam KS** *see* West ML (578)
- Addington D** *see* Canadian Psychiatric Association Scientific and Research Council (1049); Dickson RA (909); Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Addington D, Addington J, Robinson G**  
Attributional style and depression in schizophrenia 697
- Addington J** *see* Addington D (697); el-Guebaly N (264)
- Aghababian V** *see* Lançon C (893)
- Agro K** *see* Goeree R (455; 464)
- Alda M**  
Shulman KJ, Tohen M, Kutchner SP, editors. *Mood disorders across the life span*. [book review] 90  
Skolnick P, editor. *Antidepressants: new pharmacological strategies*. [book review] 281
- Al Jeshi A**  
Moclobemide response in obsessive-compulsive disorder [letter] 285
- Allain S** *see* Haggarty JM (711)
- Anand HS**  
Olanzapine in an intensive care unit [letter] 397
- Ananth J**  
Is olanzapine a mood stabilizer? [letter] 927
- Ancill RJ** *see* Kiraly SJ (92)
- Anisman H** *see* Ravindran AV (805)
- Antony MM** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)
- Arana GW** *see* Labbate LA (488)
- Arboleda-Flórez J** *see* Quan H (762)
- Armstrong H**  
Penfold PS. *Sexual abuse by health care professionals: a personal search for meaning and healing*. [book review] 918
- Armstrong S** *see* el-Guebaly N (264)
- Asghar SJ, Chue PS, Coupland NJ, Tibbo P**  
Polyglandular autoimmune syndrome type II and paranoid schizophrenia with obsessive-compulsive disorder [letter] 391
- Auquier P** *see* Lançon C (893)
- Azim HF** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)

### B

- Baigent L, Ostbye T, Fernando MLD**  
Feasibility of client reports to measure treatment outcome in schizophrenia [letter] 94
- Bain J** *see* Langevin R (775)
- Barbieri NB**  
Psychoanalytic contributions to the study of gender issues 72
- Barnard-Thompson K, Lechner P**  
Psychiatric residents' views on their training and experience regarding issues related to child abuse (769)

- Barnsley RH** *see* Thompson AH (82)
- Bartley S** *see* Lam RW (158)
- Bartoli JL** *see* Grignon S (91)
- Bassett AS** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Bassiri D** *see* Grignon S (91)
- Bastos O** *see* Petribú K (93)
- Bean G** *see* Zhang-Wong J (164)
- Beauchamp G** *see* Gagnon A (606)
- Beauchemin M-A** *see* Lapierre O (188)
- Beaudoin CM, Cox BJ**  
Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire 483
- Behchuk W** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Chair (3S); Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)
- Beck C, Silverstone P, Glor K, Dunn J**  
Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey 680
- Beiser M** *see* Zhang-Wong J (164)
- Bell RC** *see* Mai FM (478)
- Benazzi F**  
Bipolar II and unipolar atypical depression [letter] 1050  
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder [letter] 607  
Re: selective serotonin reuptake inhibitor discontinuation syndrome: putative mechanisms and prevention strategies [letter] 95  
[response] 287; *see* Markowitz JS (286)
- Benazzi F, Rossi E**  
Mania and donepezil [letter] 506
- Bennett KJ** *see* Lipman EL (604)
- Bennett VL** *see* Li X-M (605)
- Benoit F, Lesage AD**  
L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé 781
- Bernard D** *see* Lançon C (893)
- Bernier J** *see* Roy M (283)
- Bertolote JM** *see* Taborda JGV (180)
- Bird DC** *see* Dursun SM (701)
- Black DN** *see* Roy M (671)
- Blackhouse G** *see* Goeree R (455; 464)
- Blake P** *see* Cooke RG (379)
- Bland RC**  
Precursors to schizophrenia [editorial] 325
- Blank P** *see* Taborda JGV (180)
- Blin O**  
A comparative review of new antipsychotics 235
- Boisjoly H** *see* Stip E (503)
- Boivin M** *see* Trudeau M-H (583)
- Booker L** *see* Jadad AR (1025)
- Borgeat F** *see* O'Connor K (64)
- Boulay LJ** *see* Labelle A (190; 887)
- Boulter M, Steiner M**  
Stewart DE, Erlick Robinson G, editors. *A clinician's guide to menopause*. [book review] 186
- Bowman ML**  
Individual differences in posttraumatic distress: problems with the DSM-IV model 21

- Boyer R** *see* Melançon G (253)  
**Boyle MH** *see* Jadad AR (1025); MacLeod RJ (144)  
**Boyle MH, Jadad AR**  
 Lessons from large trials: the MTA Study as a model for evaluating the treatment of childhood psychiatric disorder 991  
**Brager N** *see* Tham CJ (923)  
**Brain KL** *see* Wells JH (40)  
**Brault M** *see* O'Connor K (64)  
**Breton JJ**  
 Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms 227  
**Brown A** *see* Susser EB (326)  
**Bruneau M-A** *see* Trudeau M-H (583)  
**Bryant AG** *see* Glancy GD (440)  
**Busby K** *see* Mai FM (478)

## C

- Cadotte B**  
 Re: mental health legislation and the right to appropriate treatment [letter] 504; [response] (O'Reilly R) 505  
**Calvet P** *see* Grignon S (91)  
**Cameron PM**  
 Strengthening the psychotherapies [editorial] 547  
*see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (185)  
**Canadian Psychiatric Association Psychotherapies Steering Committee Chair: Bebhuk W**  
 Psychotherapies and the practice of psychiatry 3S  
**Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1: Cameron PM, Leszcz M, Bebhuk W, Swinson RP, Antony MM, Azim HF, Doidge N, Korenblum MS, Nigam T, Perry JC, Seeman MV**  
 The practice and roles of the psychotherapies: a discussion paper 18S  
**Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2: MacKenzie KR, Leszcz M, Abbass A, Hollander Y, Kleinman I, Livesley J, Pinard G, Seeman MV**  
 Guidelines for the psychotherapies in comprehensive psychiatric care: a discussion paper 4S  
**Canadian Psychiatric Association Scientific and Research Council: Addington D, Enns M, Moamai J, Morehouse R, Porter A, Shrikande S, Styra R, Yatham L**  
 Is it time for a Canadian institute of mental illness and mental health research? [letter] 1049  
**Cardoso RG** *see* Taborda JGV (180)  
**Cernovsky Z** *see* Komer WJ (495)  
**Chaimowitz G, Ferencz J**  
 Cost savings associated with fitness-to-stand-trial assessments in detention centres: a pilot program 808  
**Challis GB**  
 Level of activity and prevalence of smoking in psychiatric patients [letter] 711  
**Charach A** *see* Hanson M (874)  
**Cherland E, Fitzpatrick R**  
 Psychotic side effects of psychostimulants: a review of 5 years of practice 811  
**Chlan-Fourney J** *see* Li X-M (605)  
**Christopherson Young P** *see* Labbate LA (488)  
**Chue P** *see* Tibbo P (276)  
**Chue PS** *see* Asghar SJ (391)  
**Cohen D** *see* Waring EW (189)  
**Cohen D, Tempier R**  
 Group treatment of substance abuse for patients with schizophrenia or related disorders [letter] 928  
**Coles EM** *see* Veiel HOF (356)  
**Conacher GN**  
 Shamasani S. *Cult fictions: CG Jung and the founding of analytical psychology*. [book review] 184  
**Cook P** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)  
**Cooke RG, Young LT, Mohri L, Blake P, Joffe RT**  
 Family-of-origin characteristics in bipolar disorder: a controlled study 379

- Cooper AJ**  
 Re: sexual recidivism in sex offenders [letter] 94  
**Cooper JP** *see* Lacika S (396)  
**Corkum P, Rimer P, Schachar R**  
 Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month treatment trial 1043  
**Cortese L, Malla AK, McLean T, Diaz JF**  
 Exploring the longitudinal course of psychotic illness: a case-study approach 881  
**Coupland NJ** *see* Asghar SJ (391)  
**Cox BJ** *see* Beaudoin CM (483)  
**Crockford D** *see* Maybaum L (922)  
**Crow S, Daly KA, Fatemi SH, MacGraw R, Meller W**  
 Citalopram: a rapid onset selective serotonin reuptake inhibitor? [letter] 1051  
**Cunningham CE**  
 In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder 999  
*see* Jadad AR (1025)  
**Cunningham J** *see* Ross HE (570)  
**Curnoe S** *see* Langevin R (775)

## D

- Dalby JT** *see* Dickson RA (909)  
**Daly KA** *see* Crow S (1051)  
**Daly KA, Fatemi SH**  
 Lamotrigine and impulse behaviour [letter] 395  
**Darves-Bornoz J-M, Degiovanni A, Gaillard P**  
 Validation of a French version of the Dissociative Experiences Scale in a rape-victim population 271  
**Davidson S**  
 Naomi Ingrid Rae-Grant [in memoriam] 973  
**de Blic J** *see* Vila G (562)  
**Degiovanni A** *see* Darves-Bornoz J-M (271)  
**de Oliveira IR** *see* Petribú K (93)  
**Deshauer D**  
 Jaspers K, Hoenig J, Hamilton MW, translators. *General psychopathology. Volume II*. [book review] 598  
**Devin PG** *see* Waring EW (189)  
**Dewan V** *see* Waring EW (189)  
**Dewan VK** *see* Waring EW (189)  
**Diaz JF** *see* Cortese L (881)  
**Dickson R** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)  
**Dickson RA, Dalby JT, Addington D, Williams R, McDougall GM**  
 Hospital days in risperidone-treated patients 909  
**Doidge N** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)  
**Doucet P**  
 Strean HS, Lapointe P, traducteur. *L'agir sexuel en thérapie : traitement et réadaptation du thérapeute déviant*. [book review] 815  
**Dubreucq J-L** *see* Lapierre O (188)  
**Dunbar S** *see* Komer WJ (495); O'Reilly (259)  
**Dunn J** *see* Beck C (680)  
**Dursun SM** *see* Izmir M (710)  
**Dursun SM, Gardner DM, Bird DC, Flinn J**  
 Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study 701  
**Dyck RJ** *see* Thompson AH (82)

## E

- el-Guebaly N**  
 Committee on Alcoholism and Addictions, Group for the Advancement of Psychiatry. *Addiction treatment: avoiding pitfalls - a case approach*. [book review] 500  
 Edwards G, Marshall EJ, Cook CC. *The treatment of drinking problems. A guide for the helping professional. Third edition*. [book review] 88

- O'Connell DF. *Dual disorders: essentials for assessment and treatment*. [book review] 89
- Pioneering aspects of psychiatry [presidential address] 868
- el-Guebaly N, Hodgins DC, Armstrong S, Addington J**  
Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity 264
- Ellis HD** *see* Joseph AB (685)
- Engelsmann F**  
Okpaku SO, editor. *Clinical methods in transcultural psychiatry*. [book review] 183
- Tseng W-S, Streltzer J, editors. *Culture and psychopathology: a guide to clinical assessment*. [book review] 386
- Enns M** *see* Canadian Psychiatric Association Scientific and Research Council (1049)
- Enns MW**  
Re: predictors of outcome in electroconvulsive therapy [letter] 921
- F**
- Fatemi SH** *see* Crow S (1051); Daly KA (395)
- Fernando MLD** *see* Baigent L (94)
- Ferencz J** *see* Chaimowitz G (808)
- Ferland F** *see* Ladouceur R (802)
- Fitzpatrick R** *see* Cherland E (811)
- Flinn J** *see* Dursun SM (701)
- Fotheringham JB**  
Living arrangement requirements for individuals with developmental disability and behavioural problems (589)
- Friedman E**  
Neurobiology of the immune system and infection in the effects of psychological factors on the cardiovascular system [letter] 284
- Friedman EH**  
Neurobiology of early antecedents of adult health problems [letter] 1052
- Friedrich M** *see* MacLeod RJ (144)
- Fry R** *see* Stalker CA (168)
- G**
- Gagnon A, Beauchamp G**  
Seasonality in hospital prevalence of adolescent psychoses: absence of variation [letter] 606
- Gaillard P** *see* Darves-Bornoz J-M (271)
- Gangadhar BN** *see* Mayur PM (191)
- Gardner DM** *see* Dursun SM (701); Haslam DRS (390)
- Garfinkel PE** *see* Kaplan AS (665)
- Garza Trevino ES** *see* Hollister LE (658)
- Gauld M** *see* Jadad AR (1025)
- Gee TL** *see* Powell RA (914)
- Geist R, Heinmaa M, Katzman D, Stephens D**  
A comparison of male and female adolescents referred to an eating disorder program 374
- Gemar M** *see* Zaretsky AE (491)
- Gendemann K** *see* Tibbo P (1049)
- Giroux I** *see* Ladouceur R (802)
- Glancy G** *see* Langevin R (775)
- Glancy GD, Regehr C, Bryant AG, Schneider R**  
A nail in the coffin of confidentiality [editorial] 440
- Glor K** *see* Beck C (680)
- Godfroid IO**  
Des variations intersexuelles relatives aux traitements en psychiatrie 362
- Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P**  
The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia 455
- Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J**  
The economic burden of schizophrenia in Canada 464
- Goering P** *see* Goeree R (455; 464)
- Goldberg J** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Goldberg J, Szatmari P, Nahmias C**  
Imaging of autism: lessons from the past to guide studies in the future 793
- Golshan S** *see* Magulac M (368)
- Gordon AG**  
Creativity, hyperesthesia, and mental illness [letter] 91
- Grauer H**  
Re: individual differences in posttraumatic distress [letter] 708
- Gray JE, Keegan D**  
Re: mental health legislation and the right to appropriate treatment [letter] 394; [response] (O'Reilly R) 503
- Greben SE**  
McCallum M, Piper WE, editors. *Psychological mindedness: a contemporary understanding*. [book review] 88
- Greenland C**  
Re: what does early antisocial behaviour predict? [letter] 604; [response] (Lipman EL, Bennett KJ, Racine YA, Offord DR, Mazumdar R) 604
- Grewal R** *see* Waring EW (189)
- Grignon S, Bassiri D, Bartoli JL, Calvet P**  
Association of Diogenes syndrome with a compulsive disorder [letter] 91
- Grizenko N** *see* Looper K (138)
- Grof P**  
How we review books [editorial] 657
- Grünberg F** *see* Trudeau M-H (583)
- Günter M, Karle M, Werning A, Klingebiel T**  
Emotional adaptation of children undergoing bone marrow transplantation 77
- H**
- Haggarty J** *see* Husni M (190)
- Haggarty JM, Husni M, Peat C, Allain S**  
Atypical neuroleptic malignant syndrome [letter] 711
- Haines J** *see* Wells JH (40)
- Hanson M, Tiberius R, Charach A, Ulzen T, Sackin D, Jain U, Reiter S, Shomair G**  
Curriculum renewal in child psychiatry 874
- Haslam DRS, Gardner DM, Oluboka T**  
Re: Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia [letter] 390; [response] (Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia: Addington D, Bassett AS, Cook P, Dickson R, Goldberg J, Honer B, Kopala L, Malla A) 391
- Heinmaa M** *see* Geist R (374)
- Hintikka J, Viinamäki H, Koskela K, Kontula O**  
Does regular attendance at sporting events promote mental health? [letter] 608
- Hoaken P**  
Resolution of complicated grief through vicarious grieving [letter] 606
- Hodgins DC** *see* el-Guebaly N (264)
- Hollander Y** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S); Mosherian P (925)
- Hollister LE, Garza Trevino ES**  
Calcium channel blockers in psychiatric disorders: a review of the literature 658
- Honer B** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Husni M** *see* Haggarty JM (711)
- Husni M, Haggarty J, Peat C**  
Clozapine does not increase ECT-seizure duration [letter] 190
- I**
- Izmir M, Dursun SM**  
Cyproterone acetate treatment of Tourette's syndrome [letter] 710

## J

- Jacques C** *see* Ladouceur R (802)
- Jadad AR** *see* Boyle MH (991)
- Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R**  
The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses 1025
- Jain U** *see* Hanson M (874)
- Jalbert M, Primeau F**  
Deafness mistaken for dementia [letter] 394
- Janakiramaiah N** *see* Mayur PM (191)
- Jeffries JJ**  
Oyewumi LK, de Wit R. *Managing side effects of psychotropic drugs: a clinical handbook for health care professionals*. [book review] 920  
*see* Schaffer A (605)
- Jensen PS**  
Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder 975
- Jerome L, Washington P, Laine CJ, Segal A**  
Graduating teachers' knowledge and attitudes about attention-deficit hyperactivity disorder: a comparison with practicing teachers [letter] 192
- Jeste DV** *see* Magulac M (368)
- Jin C, Sher L**  
Restrictive measures in a psychiatric hospital on weekdays versus on weekends or holidays [letter] 505
- Joffe RT** *see* Cooke RG (379)
- Jones PB** *see* Tarrant CJ (335)
- Joseph AB, O'Leary DH, Kurland R, Ellis HD**  
Bilateral anterior cortical atrophy and subcortical atrophy in reduplicative paramnesia: a case-control study of computed tomography in 10 patients 685
- Joseph LW**  
Greenspan SI. *Developmentally based psychotherapy*. [book review] 383  
Ingram RE, Miranda J, Segal ZV. *Cognitive vulnerability to depression*. [book review] 501  
McCullough Vaillant L. *Changing character. Short-term anxiety-regulating psychotherapy for restructuring defenses, affects, and attachment*. [book review] 383
- Jouvent R** *see* Vila G (562)
- Juorio AV** *see* Li X-M (605)
- Juralowicz P** *see* Kiraly SJ (92)

## K

- Kakuma R** *see* Jadad AR (1025)
- Kaplan AS, Garfinkel PE**  
Difficulties in treating patients with eating disorders: a review of patient and clinician variables 665
- Karle M** *see* Günter M (77)
- Katzman D** *see* Geist R (374)
- Keegan D** *see* Gray JE (394)
- Keegan DL** *see* Li X-M (605)
- Kim M** *see* Jadad AR (1025)
- Kiraly SJ, Ancill RJ, Juralowicz P, Kroeker G**  
Hypercortisolemia and post-ECT confusion [letter] 92
- Klassen A, Miller A, Raina P, Lee SK, Olsen L**  
Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies 1007
- Kleinman I** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)
- Klingebiel T** *see* Günter M (77)
- Komer W** *see* O'Reilly (259)
- Komer WJ, O'Reilly RL, Cernovsky Z, Dunbar S**  
Review Board outcomes for involuntary patients in provincial psychiatric hospital 495

- Kontula O** *see* Hintikka J (608)
- Kopala L** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)
- Korenblum MS** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)
- Koskela K** *see* Hintikka J (608)
- Krebs MO, Olie JP**  
Tardive dystonia induced by risperidone [letter] 507
- Kroeker G** *see* Kiraly SJ (92)
- Kurland R** *see* Joseph AB (685)

## L

- Labbate LA** *see* Snodgrass PL (921)
- Labbate LA, Christopherson Young P, Arana GW**  
Panic disorder in schizophrenia 488
- Labelle A, Boulay LJ**  
An attempted suicide using transdermal nicotine patches [letter] 190
- Labelle A, Boulay LJ, Lapierre YD**  
Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia 887
- Lacika S, Cooper JP**  
Pulmonary embolus possibly associated with clozapine treatment [letter] 396
- Ladouceur R, Jacques C, Ferland F, Giroux I**  
Prevalence of problem gambling: a replication study seven years later 802
- Laine CJ** *see* Jerome L (192)
- Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP**  
Clinical predictors of short-term outcome in electroconvulsive therapy 158
- Lançon C, Aghababian V, Llorca PM, Bernard D, Auquier P**  
An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale 893
- Landry M** *see* Nadeau L (592)
- Landsverk J** *see* Magulac M (368)
- Langevin R, Glancy G, Curnoe S, Bain J**  
A study of physicians who commit sexual offences 775
- Langlois R** *see* Roy M (671)
- Lapierre O, Dubreucq J-L, Beauchemin M-A, Vinet B**  
Valproic acid intoxication in a patient with bipolar disorder and chronic uremia [letter] 188
- Lapierre YD** *see* Labelle A (887); Ravindran AV (805)
- Laporte L** *see* Marleau JD (57; 924)
- Latimer EA**  
Economic impacts of assertive community treatment: a review of the literature 443
- Lauber C**  
Nefazodone withdrawal syndrome [letter] 285
- Lee SK** *see* Klassen A (1007)
- Leichner P** *see* Barnard-Thompson K (769)
- Lesage AD**  
Mentally healthier Canadians [editorial] 226  
*see* Benoit F (781)
- Leszcz M** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S); Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)
- Leung M** *see* Mosherian P (925)
- Lew V** *see* Roy M (671)
- Li X-M, Juorio AV, Chlan-Fourney J, Shrikhande S, Bennett VL, Keegan DL**  
A new mechanism for the actions of olanzapine [letter] 605
- Lin E** *see* Rhodes AE (175); Ross HE (570)
- Links PS**  
Millon T, Simonsen E, Birket-Smith M, Davis RD, editors. *Psychopathy: antisocial, criminal, and violent behavior*. [book review] 814
- Lipman E** *see* Waddell C (35S)
- Lipman EL, Bennett KJ, Racine YA, Offord DR, Mazumdar R**  
[response] 604; *see* Greenland C (604)



**Livesley J** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)

**Llorca PM** *see* Lançon C (893)

**Looper K, Grizenko N**

Risk and Protective Factors Scale: reliability and validity in preadolescents 138

**Lublinsky E** *see* Melamed Y 393

## M

**MacGraw R** *see* Crow S (1052)

**MacKenzie KR** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)

**MacLeod RJ, McNamee JE, Boyle MH, Offord DR, Friedrich M**

Identification of childhood psychiatric disorder by informant: comparisons of clinic and community samples 144

**Magulac M, Landsverk J, Golshan S, Jeste DV**

Abnormal involuntary movements in neuroleptic-naïve children and adolescents 368

**Mai FM, Busby K, Bell RC**

Clinical ratings of compliance in hemodialysis patients 478

**Malla AK** *see* Cortese L (881)

**Malla A** *see* Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia (391)

**Markowitz JC**

Developments in interpersonal psychotherapy 556

**Markowitz JS**

Re: nefazodone withdrawal symptoms [letter] 286; [response] (Benazzi F) 287

**Marks I**

Computer aids to mental health care 548

**Marleau JD, Laporte L**

Gender of victims and motivation of filicidal parents: is there a relationship? [letter] 924

**Marleau JD, Poulin B, Webanck T, Roy R, Laporte L**

Paternal filicide: a study of 10 men 57

**Matte TD** *see* Susser EB (326)

**Maybaum L, Crockford D**

Electroconvulsive therapy, personality structure, and suicide [letter] 922

**Mayur PM, Gangadhar BN, Janakiramaiah N**

Factors influencing ratio of motor and EEG seizure duration in ECT [letter] 191

**Mazeh D** *see* Melamed Y 393

**Mazumdar R** *see* Lipman EL (604)

**McCreary BD, Thompson J**

Psychiatric aspects of sexual abuse involving persons with developmental disabilities 350

**McDougall GM** *see* Dickson RA (909)

**McIntyre RS**

Antidepressants and sexual dysfunction [letter] 926

**McLean T** *see* Cortese L (881)

**McNamee JE** *see* MacLeod RJ (144)

**Melamed Y, Lublinsky E, Mazeh D**

Who will protect mentally ill individuals from themselves? [letter] 393

**Melançon G, Boyer R**

Comment prévenir l'apparition d'un trouble de stress post-traumatique avant un traumatisme ? 253

**Meller W** *see* Crow S (1052)

**Merskey H**

Re: dissociation [letter] 283

**Miller A**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives 1017

*see* Klassen A (1007)

**Mishara BL**

Suicide in the Montreal subway system: characteristics of the victims, antecedents, and implications for prevention 690

**Moamai J** *see* Canadian Psychiatric Association Scientific and Research Council (1049)

**Mohri L** *see* Cooke RG (379)

**Morehouse R** *see* Canadian Psychiatric Association Scientific and Research Council (1049)

**Mosherian P, Leung M, Hollander Y, Remick RA**

Nefazodone-induced visual disturbances [letter] 925

**Mouren-Simeoni MC** *see* Vila G (562)

**Munro A**

Eppel A, MacKay J, Pederson S, Szathmáry T, editors. *Partners in healing: perspectives on the experience of psychiatry*. [book review] 919

*see* Ravindran AV (133)

## N

**Nadeau L, Landry M, Racine S**

Prevalence of personality disorders among clients in treatment for addiction 592

**Nahmias C** *see* Goldberg J (793)

**Nigam T** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)

**Nollet-Clemençon C** *see* Vila G (562)

**Noone JA**

Webster CD, Jackson MA, editors. *Impulsivity: theory, assessment, and treatment*. [book review] 601

**Norman RMG, Townsend LA**

Cognitive-behavioural therapy for psychosis: a status report 245

## O

**O'Brien BJ** *see* Goeree R (455; 464)

**O'Connor K, Todorov C, Robillard S, Borgeat F, Brault M**

Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study 64

**Offord D** *see* Waddell C (35S)

**Offord DR** *see* Lipman EL (604); MacLeod RJ (144)

**O'Leary DH** *see* Joseph AB (685)

**Olie JP** *see* Krebs MQ (507)

**Olsen L** *see* Klassen A (1007)

**Oluboka T** *see* Haslam DRS (390)

**O'Reilly RL**

Is hospitalization bad for patients with psychiatric problems? [letter] 709

[response] 503; *see* Gray JE (394)

[response] 505; *see* Cadotte B (504)

*see* Komer WJ (495)

**O'Reilly RL, Komer W, Dunbar S**

Why are patients discharged by review boards? 259

**Ostbye T** *see* Baigent L (94)

## P

**Pakes EH**

Re: editorial I - millennium—fantasy, furor, and fact [letter] 708

**Paris J**

Does stress cause posttraumatic stress disorder [editorial] 20

Heinz Lehmann: a pioneer of modern psychiatry [in memoriam] 441

[response] 817; *see* Shatan CF (817)

[response] 818; *see* Sigal J (817)

**Patten SB**

Long-term medical conditions and major depression in the Canadian population 151

Validity of hospital-discharge data [letter] 189

**Pawliuk G** *see* Wadden P (709)

**Peat C** *see* Haggarty JM (711); Husni M (190)

**Pelham WE Jr**

The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? 981

**Perry JC** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)

**Petribú K, Bastos O, de Oliveira IR**

Level of schooling and obsessive-compulsive disorder [letter] 93

**Pinard G**

The economics of mental illness [editorial] 438

see Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)

**Plaut SM** see Weintraub W (473)

**Porter A** see Canadian Psychiatric Association Scientific and Research Council (1049)

**Poulin B** see Marleau JD (57)

**Powell RA, Gee TL**

The effects of hypnosis on dissociative identity disorder: a reexamination of the evidence 914

**Primeau F** see Jalbert M (394)

**Prince R**

Cawte J. *The last of the lunatics*. [book review] 705

**Q****Quan H, Arboleda-Florez J**

Elderly suicide in Alberta: difference by gender 762

**R**

**Racine S** see Nadeau L (592)

**Racine YA** see Lipman EL (604)

**Rae-Grant Q**

Journal update [editorial] 131

Millennium—fantasy, furor, and fact [editorial] 18

**Raina P** see Klassen A (1007)

**Ramasubbu R**

Implications of lesion—clinical correlation in poststroke depression [letter] 506

**Ravindran AV, Lapierre YD, Anisman H**

Obsessive—compulsive spectrum disorders: effective treatment with paroxetine 805

**Ravindran AV, Yatham LN, Munro A**

Paraphrenia redefined 133

**Regehr C** see Glancy GD (440)

**Reiter S** see Hanson M (874)

**Remick RA** see Mosherian P (925)

**Rhodes A** see Goeree R (464)

**Rhodes AE, Lin E, Streiner DL**

Confronting the confounders: the meaning, detection, and treatment of confounders in research 175

**Rimer P** see Corkum P (1043)

**Robert JJ** see Vila G (562)

**Robillard S** see O'Connor K

**Robinson G** see Addington D (697)

**Rose SM** see West ML (578)

**Ross HE, Lin E, Cunningham J**

Mental health service use: a comparison of treated and untreated individuals with substance-use disorders in Ontario 570

**Rossi E** see Benazzi F (506)

**Roy M, Bernier J**

A rapid response with psychostimulants in the treatment of depressed persons with medical illnesses [letter] 283

**Roy M, Stip E, Black DN, Lew V, Langlois R**

Séquelles neurologiques secondaires à une intoxication aiguë au lithium 671

**Roy R** see Marleau JD (57)

**S**

**Sackin D** see Hanson M (874)

**Sandor P** see Stephens RJ (1036)

**Scamvougeras A**

McConnell HW, Schneider PJ, editors. *Psychiatric comorbidity in epilepsy: basic mechanisms, diagnosis and treatment*. [book review] 185

**Schachar R**

The MTA: child and adolescent psychiatry in a new century [editorial] 972

see Corkum P (1043); Jadad AR (1025)

**Schaffer A, Jeffries JJ**

Delayed cognitive decline following cranial irradiation [letter] 605

**Scheinmann P** see Vila G (562)

**Schemmer DS, Siekierski M, Steiner M**

CT of the brain: how useful is it in general psychiatry? [letter] 929

**Schneider R** see Glancy GD (440)

**Seeman MV** see Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S); Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2 (4S)

**Segal A** see Jerome L (192)

**Segal ZV** see Zaretsky AE (491)

**Shatan CF**

Re: posttraumatic stress disorder [letter] 817; [response] (Paris J) 817

**Sher L** see Jin C (505)

**Shomair G** see Hanson M (874)

**Shrikhande S** see Li X-M (605)

**Shrikande S** see Canadian Psychiatric Association Scientific and Research Council (1049)

**Siekierski M** see Schemmer DS (929)

**Sigal J**

Re: posttraumatic stress disorder and exposure [letter] 817; [response] (Paris J) 818

**Silverstone PH**

Ames D, Chiu E, editors. *Neuroimaging and the psychiatry of late life*. [book review] 706

see Beck C (680)

**Snodgrass PL, Labbate LA**

Tardive dyskinesia from risperidone and olanzapine in an alcoholic man [letter] 921

**Spreng SW** see West ML (578)

**Stalker CA, Fry R**

A comparison of short-term group and individual therapy for sexually abused women 168

**Steele MM, Veitch Wolfe V**

Child psychiatry practice patterns in Ontario 788

**Steinberg PI**

Gutheil TG. *The psychiatrist in court; a survival guide*. and *The psychiatrist as expert witness*. [book review] 600

Ronningstam EF, editor. *Disorders of narcissism: diagnostic, clinical, and empirical implications*. [book review] 87

Savege Scharff J, Scharff DE. *Object relations individual therapy*. [book review] 499

**Steiner M**

Feldman RS, Meyer JS, Quenzer LF. *Principles of neuropsychopharmacology*. [book review] 282

see Boulter M (186); Schemmer DS (929)

**Stephens D** see Geist R (374)

**Stephens RJ, Sandor P**

Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive—compulsive disorder 1036

**Stip E** see Roy M (671); Trudeau M-H (583)

**Stip E, Boisjoly H**

Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? [letter] 503

**Streiner D**

Pincus HA, Lieberman JA, Ferris S, editors. *Ethics in psychiatric research: a resource manual for human subjects protection*. [book review] 384

Stein DJ, Ludik J, editors. *Neural networks and psychopathology*. [book review] 599

**Streiner DL** see Rhodes AE (175)

**Styra R** see Canadian Psychiatric Association Scientific and Research Council (1049)

**Susser EB, Brown A, Matte TD**

Prenatal factors and adult mental and physical health 326

**Swinson RP** *see* Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1 (18S)

**Szatmari P** *see* Goldberg J (793)

## T

**Taborda JGV, Bertolote JM, Cardoso RG, Blank P**

The impact of primary mental health care in a prison system in Brazil 180

**Tam EM** *see* Lam RW (158)

**Tarrant CJ, Jones PB**

Precursors to schizophrenia: do biological markers have specificity? 335

**Telner JJ**

Markowitz JC. *Interpersonal psychotherapy for dysthymic disorder*. [book review] 382

Millon T. *The Millon Inventories: clinical and personality assessment*. [book review] 280

**Tempier R** *see* Cohen D (928)

**Tham CJ, Trew M, Brager N**

Abnormal clotting and production of factor VIII inhibitor in a patient treated with venlafaxine [letter] 923

**Thompson AH, Barnsley RH, Dyck RJ**

A new factor in youth suicide: the relative age effect 82

**Thompson J** *see* McCreary BD (350)

**Tibbo P** *see* Asghar SJ (391)

**Tibbo P, Chue P, Wright E**

Hospital outcome measures following assertive community treatment in Edmonton, Alberta 276

**Tibbo P, Gendemann K**

Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia [letter] 1050

**Tiberius R** *see* Hanson M (874)

**Todorov C** *see* O'Connor K (64)

**Townsend LA** *see* Norman RMG (245)

**Tremblay RE** *see* Vitaro F (901)

**Trew M** *see* Tham CJ (923)

**Trudeau M-H, Bruneau M-A, Stip E, Grünberg F, Boivin M**

Refus catégorique de traitement des patients psychiatriques : bilan, enquête et perspective 583

## U

**Ulzen T** *see* Hanson M (874)

## V

**Veiel HOF, Coles EM**

Measuring unfitness to stand trial: psychological analysis of a legal issue 356

**Veitch Wolfe V** *see* Steele MM (788)

**Vera M** *see* Vila G (562)

**Viinamäki H** *see* Hintikka J (608)

**Vila G, Nollet-Clemençon C, Vera M, Robert JJ, de Blic J, Jouvent R, Mouren-Simeoni MC, Scheinmann P**

Prevalence of DSM-IV disorders in children and adolescents with asthma versus diabetes 562

**Vinet B** *see* Lapierre O (188)

**Vitaro F, Tremblay RE, Zoccolillo M**

Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection 901

## W

**Waddell C, Lipman E, Offord D**

Conduct disorder: practice parameters for assessment, treatment, and prevention 35S

**Wadden P, Pawliuk G**

Cessation of nail-biting and bupropion [letter] 709

**Wallot H**

Évaluation du potentiel de ressources communautaires en santé mentale 48

**Waring EW, Devin PG, Dewan V**

Treatment of schizophrenia with antipsychotics in combination [letter] 189

**Waring EW, Dewan VK, Cohen D, Grewal R**

Risperidone as an adjunct to valproic acid [letter] 189

**Washington P** *see* Jerome L (192)

**Watson J** *see* Goeree R (464)

**Webanck T** *see* Marleau JD (57)

**Weintraub E** *see* Weintraub W (473)

**Weintraub W, Plaut SM, Weintraub E**

Recruitment into psychiatry: increasing the pool of applicants 473

**Wells JH, Haines J, Williams CL, Brain KL**

The self-mutilative nature of severe onychophagia: a comparison with self-cutting 40

**Werning A** *see* Günter M (77)

**West ML, Spreng SW, Rose SM, Adam KS**

Relationship between attachment-felt security and history of suicidal behaviours in clinical adolescents 578

**Williams CL** *see* Wells JH (40)

**Williams R** *see* Dickson RA (909)

**Wilson A**

McMance-Katz EF, Kosten TR. *New treatments for chemical addictions*. [book review] 603

**Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia: Addington D, Bassett AS, Cook P, Dickson R, Goldberg J, Honer B, Kopala L, Malla A**

[response] 391; *see* Haslam DRS (390)

**Wright E** *see* Tibbo P (276)

## Y

**Yatham L** *see* Canadian Psychiatric Association Scientific and Research Council (1049)

**Yatham LN** *see* Lam RW (158); Ravindran AV (133)

**Yehuda R**

Biological factors associated with susceptibility to posttraumatic stress disorder 34

**Young LT** *see* Cooke RG (379)

## Z

**Zaretsky AE, Segal ZV, Gamar M**

Cognitive therapy for bipolar depression: a pilot study 491

**Zhang-Wong J, Zipursky RB, Beiser M, Bean G**

Optimal haloperidol dosage in first-episode psychosis 164

**Zipursky RB** *see* Zhang-Wong J (164)

**Zis AP** *see* Lam RW (158)

**Zoccolillo M** *see* Vitaro F (901)

## Subject Index

### A

#### abus de psychotropes

Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection (Vitaro F, Tremblay RE, Zoccolillo M) 901

#### acceptability

Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month treatment trial (Corkum P, Rimer P, Schachar R) 1043

#### active learning

Curriculum renewal in child psychiatry (Hanson M, Tiberius R, Charach A, Ulzen T, Sackin D, Jain U, Reiter S, Shomair G) 874

#### activity

Level of activity and prevalence of smoking in psychiatric patients [letter] (Challis GB) 711

#### adherence

Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month treatment trial (Corkum P, Rimer P, Schachar R) 1043

#### adolescent psychoses

Seasonality in hospital prevalence of adolescent psychoses: absence of variation [letter] (Gagnon A, Beauchamp G) 606

#### adolescents

A comparison of male and female adolescents referred to an eating disorder program (Geist R, Heinmaa M, Katzman D, Stephens D) 374



- Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227
- The MTA: child and adolescent psychiatry in a new century [editorial] (Schachar R) 972
- Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection (Vitaro F, Tremblay RE, Zoccolillo M) 901
- Prevalence of DSM-IV disorders in children and adolescents with asthma versus diabetes (Vila G, Nollet-Clemençon C, Vera M, Robert JJ, de Blic J, Jouvencé R, Mouren-Simeoni MC, Scheinmann P) 562
- Relationship between attachment-felt security and history of suicidal behaviours in clinical adolescents (West ML, Spreng SW, Rose SM, Adam KS) 578
- adult attention-deficit hyperactivity disorder**
- Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Gior K, Dunn J) 680
- adverse effects**
- The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025
- aged**
- Elderly suicide in Alberta: difference by gender (Quan H, Arboleda-Florez J) 762
- aggression**
- A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775
- aggressive behaviour**
- Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive-compulsive disorder (Stephens RJ, Sandor P) 1036
- Alberta**
- Elderly suicide in Alberta: difference by gender (Quan H, Arboleda-Florez J) 762
- alcohol**
- Computer aids to mental health care (I Marks) 548
- alcoolisme**
- Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection (Vitaro F, Tremblay RE, Zoccolillo M) 901
- amphetamine**
- Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Gior K, Dunn J) 680
- anorexia nervosa**
- Difficulties in treating patients with eating disorders: a review of patient and clinician variables (Kaplan AS, Garfinkel PE) 665
- antecedents**
- Neurobiology of early antecedents of adult health problems [letter] (Friedman EH) 1053
- Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335
- antidepressants**
- Antidepressants and sexual dysfunction [letter] (McIntyre RS) 926
- Clinical predictors of short-term outcome in electroconvulsive therapy (Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP) 158
- antipsychotics**
- Abnormal involuntary movements in neuroleptic-naïve children and adolescents (Magulac M, Landsverk J, Golshan S, Jeste DV) 368
- A comparative review of new antipsychotics (Blin O) 235
- Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study (Dursun SM, Gardner DM, Bird DC, Flinn J) 701
- Séquelles neurologiques secondaires à une intoxication aiguë au lithium (Roy M, Stip E, Black DN, Lew V, Langlois R) 671
- Treatment of schizophrenia with antipsychotics in combination [letter] (Waring EW, Devin PG, Dewan V) 189
- antisocial behaviour**
- Conduct disorder: practice parameters for assessment, treatment, and prevention (Waddell C, Lipman E, Offord D) 355
- Re: what does early antisocial behaviour predict? [letter] (Greenland C) 604; [response] (Lipman EL, Bennett KJ, Racine VA, Offord DR, Mazumdar R) 604
- anxiety**
- Computer aids to mental health care (I Marks) 548
- Panic disorder in schizophrenia (Labbate LA, Christopherson Young P, Arana GW) 488
- anxiety disorders**
- Computer aids to mental health care (I Marks) 548
- appropriateness of affect**
- Paraphrenia redefined (Ravindran AV, Yatham LN, Munro A) 133
- assertive community treatment**
- Economic impacts of assertive community treatment: a review of the literature (Latimer EA) 443
- Hospital outcome measures following assertive community treatment in Edmonton, Alberta (Tibbo P, Chue P, Wright E) 276
- assessment**
- Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire (Beaudoin CM, Cox BJ) 483
- Conduct disorder: practice parameters for assessment, treatment, and prevention (Waddell C, Lipman E, Offord D) 355
- asthma**
- Prevalence of DSM-IV disorders in children and adolescents with asthma versus diabetes (Vila G, Nollet-Clemençon C, Vera M, Robert JJ, de Blic J, Jouvencé R, Mouren-Simeoni MC, Scheinmann P) 562
- ataxia**
- Séquelles neurologiques secondaires à une intoxication aiguë au lithium (Roy M, Stip E, Black DN, Lew V, Langlois R) 671
- attachment**
- Relationship between attachment-felt security and history of suicidal behaviours in clinical adolescents (West ML, Spreng SW, Rose SM, Adam KS) 578
- attention deficit**
- Lessons from large trials: the MTA Study as a model for evaluating the treatment of childhood psychiatric disorder (Boyle MH, Jadad AR) 991
- Psychotic side effects of psychostimulants: a review of 5 years of practice (Cherland E, Fitzpatrick R) 811
- The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025
- attention-deficit hyperactivity disorder**
- Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive-compulsive disorder (Stephens RJ, Sandor P) 1036
- Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017
- Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies (Klassen A, Miller A, Raina P, Lee SK, Olsen T) 1007
- Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975
- Graduating teachers' knowledge and attitudes about attention-deficit hyperactivity disorder: a comparison with practicing teachers [letter] (Jerome L, Washington P, Laine CJ, Segal A) 192
- In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder (Cunningham CE) 999
- Lessons from large trials: the MTA Study as a model for evaluating the treatment of childhood psychiatric disorder (Boyle MH, Jadad AR) 991
- The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? (Pelham WE Jr) 981
- Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month treatment trial (Corkum P, Rimer P, Schachar R) 1043
- attributional style**
- Attributional style and depression in schizophrenia (Addington D, Addington J, Robinson G) 697
- atypical psychosis**
- Paraphrenia redefined (Ravindran AV, Yatham LN, Munro A) 133
- autism, infantile**
- Imaging of autism: lessons from the past to guide studies in the future (Goldberg J, Szatmari P, Nahmias C) 793
- availability and pathological gambling**
- Prevalence of problem gambling: a replication study seven years later (Ladouceur R, Jacques C, Ferland F, Giroux I) 802

## B

**behavioural interventions**

In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder (Cunningham CE) 999

**behavioural problems**

Living arrangement requirements for individuals with developmental disability and behavioural problems (Fotheringham JB) 589

**behavioural rating scales**

Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies (Klassen A, Miller A, Raina P, Lee SK, Olsen L) 1007

**behavioural therapy**

Computer aids to mental health care (I Marks) 548

Lessons from large trials: the MTA Study as a model for evaluating the treatment of childhood psychiatric disorder (Boyle MH, Jadao AR) 991

The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? (Pelham WE Jr) 981

The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadao AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025

**bias**

Confronting the confounders: the meaning, detection, and treatment of confounders in research (Rhodes AE, Lin E, Streiner DL) 175

**bipolar disorder**

Cognitive therapy for bipolar depression: a pilot study (Zaretsky AE, Segal ZV, Gamar M) 491

Family-of-origin characteristics in bipolar disorder: a controlled study (Cooke RG, Young LT, Mohri L, Blake P, Joffe RT) 379

Valproic acid intoxication in a patient with bipolar disorder and chronic uremia [letter] (Lapierre O, Dubreucq J-L, Beauchemin M-A, Vinet B) 188

**bipolar schizoaffective disorder**

Olanzapine-induced psychotic mania in bipolar schizoaffective disorder [letter] (Benazzi F) 607

**biology**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

**birth cohort**

Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335

**bone marrow transplantation**

Emotional adaptation of children undergoing bone marrow transplantation (Günter M, Karle M, Werning A, Klingebiel T) 77

**book reviews**

How we review books [editorial] (Grof P) 657

**book reviews, addiction**

Committee on Alcoholism and Addictions, Group for the Advancement of Psychiatry. *Addiction treatment: avoiding pitfalls – a case approach*. el-Guebaly N 500

Edwards G, Marshall EJ, Cook CC. *The treatment of drinking problems. A guide for the helping professional. Third edition*. el-Guebaly N 88

O'Connell DF. *Dual disorders: essentials for assessment and treatment*. el-Guebaly N 89

McMance-Katz EF, Kosten TR. *New treatments for chemical addictions*. Wilson A 603

**book reviews, l'agir sexuel en thérapie**

Strean HS, Lapointe P, traducteur. *L'agir sexuel en thérapie : traitement et réadaptation du thérapeute déviant*. Doucet P 815

**book reviews, biological psychiatry**

Skolnick P, editor. *Antidepressants: new pharmacological strategies*. Alda M 281

Feldman RS, Meyer JS, Quenzer LF. *Principles of neuropsychopharmacology*. Steiner M 282

**book reviews, ethics**

Pincus HA, Lieberman JA, Ferris S, editors. *Ethics in psychiatric research: a resource manual for human subjects protection*. Streiner D 384

**book reviews, forensic psychiatry**

Gutheil TG. *The psychiatrist in court: a survival guide*. and *The psychiatrist as expert witness*. Steinberg PI 600

Webster CD, Jackson MA, editors. *Impulsivity: theory, assessment, and treatment*. Noone JA 601

**book reviews, general psychiatry**

Eppel A, MacKay J, Pederson S, Szathmáry T, editors. *Partners in healing: perspectives on the experience of psychiatry*. Munro A 919

Oyewumi LK, de Wit R. *Managing side effects of psychotropic drugs: a clinical handbook for health care professionals*. Jeffries JJ 920

McCallum M, Piper WE, editors. *Psychological mindedness: a contemporary understanding*. Greben SE 88

McConnell HW, Schneider PJ, editors. *Psychiatric comorbidity in epilepsy: basic mechanisms, diagnosis and treatment*. Scamvougeras A 185

Millon T. *The Millon Inventories: clinical and personality assessment*. Telner JI 280

Ronningstam EF, editor. *Disorders of narcissism: diagnostic, clinical, and empirical implications*. Steinberg P 87

**book reviews, geriatric psychiatry**

Ames D, Chiu E, editors. *Neuroimaging and the psychiatry of late life*. Silverstone PH 706

**book reviews, history of psychiatry**

Cawte J. *The last of the lunatics*. Prince R 705

Shamdasani S. *Cult fictions: CG Jung and the founding of analytical psychology*. Conacher GN 184

**book reviews, mood disorders**

Ingram RE, Miranda J, Segal ZV. *Cognitive vulnerability to depression*. Joseph L 501

Markowitz JC. *Interpersonal psychotherapy for dysthymic disorder*. Telner JI 382

Shulman KI, Tohen M, Kutcher SP, editors. *Mood disorders across the life span*. Alda M 90

**book reviews, neuropsychiatry**

Ames D, Chiu E, editors. *Neuroimaging and the psychiatry of late life*. Silverstone PH 706

McConnell HW, Schneider PJ, editors. *Psychiatric comorbidity in epilepsy: basic mechanisms, diagnosis and treatment*. Scamvougeras A 185

**book reviews, personality disorders**

Millon T, Simonsen E, Birket-Smith M, Davis RD, editors. *Psychopathy: antisocial, criminal, and violent behavior*. Links PS 814

**book reviews, psychology**

Millon T, editor. *The Millon Inventories: clinical and personality assessment*. Telner JI 280

**book reviews, psychopathology**

Jaspers K, Hoenig J, Hamilton MW, translators. *General psychopathology. Volume II*. Deshauser D 598

Stein DJ, Ludik J, editors. *Neural networks and psychopathology*. Streiner DL 599

**book reviews, psychotherapy**

Greenspan SI. *Developmentally based psychotherapy*. Joseph LW 383

Markowitz JC. *Interpersonal psychotherapy for dysthymic disorder*. Telner JI 382

McCullough Vaillant L. *Changing character. Short-term anxiety-regulating psychotherapy for restructuring defenses, affects, and attachment*. Joseph LW 383

Savege Scharff J, Scharff DE. *Object relations individual therapy*. Steinberg PI 499

**book reviews, sexual abuse**

Penfold PS. *Sexual abuse by health care professionals: a personal search for meaning and healing*. Armstrong H 918

**book reviews, substance abuse**

Committee on Alcoholism and Addictions, Group for the Advancement of Psychiatry. *Addiction treatment: avoiding pitfalls – a case approach*. el-Guebaly N 500

**book reviews, transcultural psychiatry**

Okpaku SO, editor. *Clinical methods in transcultural psychiatry*. Engelsmann F 183

Tseng W-S, Streltzer J, editors. *Culture and psychopathology: a guide to clinical assessment*. Engelsmann F 386

**book reviews, women's health**

Stewart DE, Erlick Robinson G, editors. *A clinician's guide to menopause*. Boulter M, Steiner M 186

**brain imaging**

Bilateral anterior cortical atrophy and subcortical atrophy in reduplicative paramnesia: a case-control study of computed tomography in 10 patients (Joseph AB, O'Leary DH, Kurland R, Ellis HD) 685

**bulimia nervosa**

Difficulties in treating patients with eating disorders: a review of patient and clinician variables (Kaplan AS, Garfinkel PE) 665

**bupropion**

Cessation of nail-biting and bupropion [letter] (Wadden P, Pawliuk G) 709

**C****calcium channel blockers**

Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

**Canada**

The economic burden of schizophrenia in Canada (Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J) 464

Is it time for a Canadian institute of mental illness and mental health research? [letter] (Canadian Psychiatric Association Scientific and Research Council: Addington D, Enns M, Moamai J, Morehouse R, Porter A, Shrikande S, Styra R, Yatham L) 1049

Mentally healthier Canadians [editorial] (Lesage A) 226

**Canadian comparison**

A comparison of male and female adolescents referred to an eating disorder program (Geist R, Heinmaa M, Katzman D, Stephens D) 374

**cardiovascular disease**

Prenatal factors and adult mental and physical health (Susser EB, Brown A, Matte TD) 326

**caregivers**

Living arrangement requirements for individuals with developmental disability and behavioural problems (Fotheringham JB) 589

**cataracts**

Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? [letter] (Stip E, Boisjoly H) 503

**cerebellum**

Séquelles neurologiques secondaires à une intoxication aiguë au lithium (Roy M, Stip E, Black DN, Lew V, Langlois R) 671

**chaos theory**

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

**child abuse**

Psychiatric residents' views on their training and experience regarding issues related to child abuse (Barnard-Thompson K, Leichner P) 769

**child psychiatry**

Child psychiatry practice patterns in Ontario (Steele MM, Veitch Wolfe V) 788

Risk and Protective Factors Scale: reliability and validity in preadolescents (Looper K, Grizenko N) 138

Curriculum renewal in child psychiatry (Hanson M, Tiberius R, Charach A, Ulzen T, Sackin D, Jain U, Reiter S, Shomair G) 874

The MTA: child and adolescent psychiatry in a new century [editorial] (Schachar R) 972

**childhood disorder**

Identification of childhood psychiatric disorder by informant: comparisons of clinic and community samples (MacLeod RJ, McNamee JE, Boyle MH, Offord DR, Friedrich M) 144

**children**

Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive-compulsive disorder (Stephens RJ, Sendor P) 1036

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

A new factor in youth suicide: the relative age effect (Thompson AH, Barnsley RH, Dyck RJ) 82

Prevalence of DSM-IV disorders in children and adolescents with asthma versus diabetes (Vila G, Nolllet-Clemençon C, Vera M, Robert JJ, de Blic J, Jouvencat R, Mouren-Simeoni MC, Scheinmann P) 562

Psychotic side effects of psychostimulants: a review of 5 years of practice (Cherland E, Fitzpatrick R) 811

**children of Holocaust survivors**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

**chronic medical conditions**

Long-term medical conditions and major depression in the Canadian population (Patten SB) 151

**chronic mental illness**

Hospital outcome measures following assertive community treatment in Edmonton, Alberta (Tibbo P, Chue P, Wright E) 276

**citalopram**

Citalopram: a rapid onset selective serotonin reuptake inhibitor? [letter] (Crow S, Daly KA, Fatemi SH, MacGraw R, Meller W) 1052

**clients**

Évaluation du potentiel de ressources communautaires en santé mentale (Walot H) 48

**clinical**

Relationship between attachment-felt security and history of suicidal behaviours in clinical adolescents (West ML, Spreng SW, Rose SM, Adam KS) 578

**clinical referral**

Identification of childhood psychiatric disorder by informant: comparisons of clinic and community samples (MacLeod RJ, McNamee JE, Boyle MH, Offord DR, Friedrich M) 144

**clinical training**

Developments in interpersonal psychotherapy (Markowitz JC) 556

**clinical trials**

Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975

Lessons from large trials: the MTA Study as a model for evaluating the treatment of childhood psychiatric disorder (Boyle MH, Jadad AR) 991

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapierre YD) 887

**clozapine**

Clozapine does not increase ECT-seizure duration [letter] (Husni M, Hagarty J, Peat C) 190

Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia [letter] (Tibbo P, Gendemann K) 1050

Pulmonary embolus possibly associated with clozapine treatment [letter] (Lacka S, Cooper JP) 396

**cognitive-behavioural therapy**

Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study (O'Connor K, Todorov C, Robillard S, Borgeat F, Brault M) 64

Cognitive-behavioural therapy for psychosis: a status report (Norman RMG, Townsend LA) 245

Computer aids to mental health care (Marks I) 548

**cognitive decline**

Delayed cognitive decline following cranial irradiation [letter] (Schaffer A, Jeffries JJ) 605

**cognitive side effects**

Clinical predictors of short-term outcome in electroconvulsive therapy (Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP) 158

**cognitive therapy**

Cognitive therapy for bipolar depression: a pilot study (Zaretsky AE, Segal ZV, Gemar M) 491

**Combined Accelerated Program in Psychiatry**

Recruitment into psychiatry: increasing the pool of applicants (Weintraub W, Plaut SM, Weintraub E) 473

**combined interventions**

In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder (Cunningham CE) 999

The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? (Pelham WE Jr) 981

**community supports**

Economic impacts of assertive community treatment: a review of the literature (Latimer EA) 443

**comorbidity**

Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive-compulsive disorder (Stephens RJ, Sendor P) 1036

Long-term medical conditions and major depression in the Canadian population (Patten SB) 151

Mental health service use: a comparison of treated and untreated individuals with substance-use disorders in Ontario (Ross HE, Lin E, Cunningham J) 570

Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity (el-Guebaly N, Hodgins DC, Armstrong S, Addington J) 264

Panic disorder in schizophrenia (Labbate LA, Christopherson Young P, Arana GW) 488

**competence**

Who will protect mentally ill individuals from themselves? [letter] (Melamed Y, Lublinsky E, Mazeh D) 393

**compliance**

Clinical ratings of compliance in hemodialysis patients (Mai FM, Busby K, Bell RC) 478

**compulsive disorder**

Association of Diogenes syndrome with a compulsive disorder [letter] (Grignon S, Bassiri D, Bartoli JL, Calvet P) 91

**computed tomography**

CT of the brain: how useful is it in general psychiatry? [letter] (Schemmer DS, Siekierski M, Steiner M) 929

**computer**

Computer aids to mental health care (Marks I) 548

**conduct disorder**

Conduct disorder: practice parameters for assessment, treatment, and prevention (Waddell C, Lipman E, Offord D) 355

**confidentiality**

A nail in the coffin of confidentiality [editorial] (Glancy GD, Regehr C, Bryant AG, Schneider R) 440

**confounding**

Confronting the confounders: the meaning, detection, and treatment of confounders in research (Rhodes AE, Lin E, Streiner DL) 175

**cortisol**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

**cost**

The economic burden of schizophrenia in Canada (Goeree R, O'Brien BJ, Goring P, Blackhouse G, Agro K, Rhodes A, Watson J) 464

Economic impacts of assertive community treatment: a review of the literature (Latimer EA) 443

**course of illness**

Exploring the longitudinal course of psychotic illness: a case-study approach (Cortese L, Malla AK, McLean T, Diaz JF) 881

**creativity**

Creativity, hyperesthesia, and mental illness [letter] (Gordon AG) 91

**curriculum renewal**

Curriculum renewal in child psychiatry (Hanson M, Tiberius R, Charach A, Ulzen T, Sackin D, Jain U, Reiter S, Shomair G) 874

**cyproterone acetate**

Cyproterone acetate treatment of Tourette's syndrome [letter] (Izmir M, Duran SM) 710

**D****deafness**

Deafness mistaken for dementia [letter] (Jalbert M, Primeau F) 394

**defence mechanisms**

Emotional adaptation of children undergoing bone marrow transplantation (Günter M, Karle M, Werning A, Klingebiel T) 77

**delayed effects**

Prenatal factors and adult mental and physical health (Susser EB, Brown A, Matte T) 326

**delusional misidentification**

Bilateral anterior cortical atrophy and subcortical atrophy in reduplicative paramnesia: a case-control study of computed tomography in 10 patients (Joseph AB, O'Leary DH, Kurland R, Ellis HD) 685

**dementia**

Deafness mistaken for dementia [letter] (Jalbert M, Primeau F) 394

**depression**

Attributional style and depression in schizophrenia (Addington D, Addington J, Robinson G) 697

Bipolar II and unipolar atypical depression [letter] (Benazzi F) 1051

Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire (Beaudoin CM, Cox BJ) 483

Cognitive therapy for bipolar depression: a pilot study (Zaretsky AE, Segal ZV, Gemar M) 491

Computer aids to mental health care (Marks I) 548

Developments in interpersonal psychotherapy (Markowitz JC) 556

Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Gior K, Dunn J) 680

**depressive disorders**

Clinical predictors of short-term outcome in electroconvulsive therapy (Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP) 158

Long-term medical conditions and major depression in the Canadian population (Patten SB) 151

A rapid response with psychostimulants in the treatment of depressed persons with medical illnesses [letter] (Roy M, Bernier J) 283

**detention centre**

Cost savings associated with fitness-to-stand-trial assessments in detention centres: a pilot program (Chaimowitz G, Ferencz J) 808

**development**

A new factor in youth suicide: the relative age effect (Thompson AH, Barnsley RH, Dyck RJ) 82

**developmental disability**

Living arrangement requirements for individuals with developmental disability and behavioural problems (Fotheringham JB) 589

Psychiatric aspects of sexual abuse involving persons with developmental disabilities (McCreary BD, Thompson J) 350

**diabetes**

Prevalence of DSM-IV disorders in children and adolescents with asthma versus diabetes (Vila G, Nollet-Clemençon C, Vera M, Robert JJ, de Blic J, Jouvent R, Mouren-Simeoni MC, Scheinmann P) 562

**Diogenes syndrome**

Association of Diogenes syndrome with a compulsive disorder [letter] (Grignon S, Bassiri D, Bartoli JL, Calvet P) 91

**disability**

Long-term medical conditions and major depression in the Canadian population (Patten SB) 151

**disruptive behaviour disorders**

Risk and Protective Factors Scale: reliability and validity in preadolescents (Looper K, Grizenko N) 138

**dissociation**

Re: dissociation [letter] (Merskey H) 283

**dissociative disorders**

Validation of a French version of the Dissociative Experiences Scale in a rape-victim population (Darves-Bornoz J-M, Degiovanni A, Gaillard P) 271

**dissociative identity disorder**

The effects of hypnosis on dissociative identity disorder: a reexamination of the evidence (Powell RA, Gee TL) 914

**donepezil**

Mania and donepezil [letter] (Benazzi F, Rossi E) 506

**dopamine**

A comparative review of new antipsychotics (Blin O) 235

**double-blind**

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapierre YD) 887

**DSM classification**

Individual differences in posttraumatic distress: problems with the DSM-IV model (Bowman ML) 21

**dynamic psychiatry**

Psychoanalytic contributions to the study of gender issues (Barbieri NB) 72

**E****eating disorders**

A comparison of male and female adolescents referred to an eating disorder program (Geist R, Heinmaa M, Katzman D, Stephens D) 374

Difficulties in treating patients with eating disorders: a review of patient and clinician variables (Kaplan AS, Garfinkel PE) 665

**economic outcomes**

Economic impacts of assertive community treatment: a review of the literature (Latimer EA) 443

The economics of mental illness [editorial] (Pinard G) 438

**effectiveness**

Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975

**efficacité thérapeutique**

Des variations intersexuelles relatives aux traitements en psychiatrie (Godfroid IO) 362

**efficacy**

Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975



**electroconvulsive therapy**

Clinical predictors of short-term outcome in electroconvulsive therapy (Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP) 158

Clozapine does not increase ECT-seizure duration [letter] (Husni M, Haggarty J, Peat C) 190

Electroconvulsive therapy, personality structure, and suicide [letter] (Maybaum L, Crockford D) 922

Factors influencing ratio of motor and EEG seizure duration in ECT [letter] (Mayur PM, Gangadhar BN, Janakiramaiah N) 191

Hypercortisolemia and post-ECT confusion [letter] (Király SJ, Ancill RJ, Jurawicz P, Kroecker G) 92

Re: predictors of outcome in electroconvulsive therapy [letter] (Enns MW) 921

**emotional adaptation**

Emotional adaptation of children undergoing bone marrow transplantation (Günter M, Karle M, Werning A, Klingebiel T) 77

**endocrine**

A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775

**enfants**

Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection (Vitaro F, Tremblay RE, Zoccolillo M) 901

**epidemiologic methods**

Confronting the confounders: the meaning, detection, and treatment of confounders in research (Rhodes AE, Lin E, Streiner DL) 175

**epidemiology**

Mental health service use: a comparison of treated and untreated individuals with substance-use disorders in Ontario (Ross HE, Lin E, Cunningham J) 570

**evaluation**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017

**évaluation**

Évaluation du potentiel de ressources communautaires en santé mentale (Wal-lot H) 48

**F****facteurs de risque**

Comment prévenir l'apparition d'un trouble de stress post-traumatique avant un traumatisme ? (Mélangeon G, Boyer R) 253

**facteurs sexuels**

Des variations intersexuelles relatives aux traitements en psychiatrie (God-froid IO) 362

**factors**

Exploring the longitudinal course of psychotic illness: a case-study approach (Cortese L, Malla AK, McLean T, Diaz JF) 881

**familicide**

Paternal filicide: a study of 10 men (Marleau JD, Poulin B, Webanck T, Roy R, Laporte L) 57

**family**

Living arrangement requirements for individuals with developmental disability and behavioural problems (Fotheringham JB) 589

**Family Environment Scale**

Family-of-origin characteristics in bipolar disorder: a controlled study (Cooke RG, Young LT, Mohri L, Blake P, Joffe RT) 379

**family functioning**

Family-of-origin characteristics in bipolar disorder: a controlled study (Cooke RG, Young LT, Mohri L, Blake P, Joffe RT) 379

**female**

A comparison of male and female adolescents referred to an eating disorder program (Geist R, Heinmaa M, Katzman D, Stephens D) 374

**femininity**

Psychoanalytic contributions to the study of gender issues (Barbieri NB) 72

**filicide**

Gender of victims and motivation of filicidal parents: is there a relationship? [letter] (Marleau JD, Laporte L) 924

Paternal filicide: a study of 10 men (Marleau JD, Poulin B, Webanck T, Roy R, Laporte L) 57

**first-episode psychosis**

Optimal haloperidol dosage in first-episode psychosis (Zhang-Wong J, Zipursky RB, Beiser M, Bean G) 164

**fitness to stand trial**

Cost savings associated with fitness-to-stand-trial assessments in detention centres: a pilot program (Chaimowitz G, Ferencz J) 808

Measuring unfitness to stand trial: psychological analysis of a legal issue (Veiel HOF, Coles EM) 356

**forensic**

Cost savings associated with fitness-to-stand-trial assessments in detention centres: a pilot program (Chaimowitz G, Ferencz J) 808

**forensic assessment**

Measuring unfitness to stand trial: psychological analysis of a legal issue (Veiel HOF, Coles EM) 356

**forensic psychiatric care**

The impact of primary mental health care in a prison system in Brazil (Taborda JGV, Bertolote JM, Cardoso RG, Blank P) 180

**foster care**

Abnormal involuntary movements in neuroleptic-naïve children and adolescents (Magulac M, Landsverk J, Golshan S, Jeste DV) 368

**friction-cost method**

The economic burden of schizophrenia in Canada (Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J) 464

The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia (Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P) 455

**G****gambling**

Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire (Beaudoin CM, Cox BJ) 483

Prevalence of problem gambling: a replication study seven years later (Ladouceur R, Jacques C, Ferland F, Giroux I) 802

**gender**

Prevalence of personality disorders among clients in treatment for addiction (Nadeau L, Landry M, Racine S) 592

Psychoanalytic contributions to the study of gender issues (Barbieri NB) 72

**gender differences**

Elderly suicide in Alberta: difference by gender (Quan H, Arboleda-Flórez J) 762

**grief**

Resolution of complicated grief through vicarious grieving [letter] (Hoaken P) 606

**group treatment outcome**

A comparison of short-term group and individual therapy for sexually abused women (Stalker CA, Fry R) 168

**guidelines**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017

Guidelines for the psychotherapies in comprehensive psychiatric care: a discussion paper (Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2) 45

The practice and roles of the psychotherapies: a discussion paper (Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1) 185

Psychotherapies and the practice of psychiatry (Canadian Psychiatric Association Psychotherapies Steering Committee Chair) 35

Re: Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia [letter] (Haslam DRS, Gardner DM, Oluboka T) 390; [response] (Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia: Addington D, Bassett AS, Cook P, Dickson R, Goldberg J, Honer B, Kopala L, Malla A) 391

**H****haloperidol optimal treatment**

Optimal haloperidol dosage in first-episode psychosis (Zhang-Wong J, Zipursky RB, Beiser M, Bean G) 164

**haloperidol plasma level**

Optimal haloperidol dosage in first-episode psychosis (Zhang-Wong J, Zipursky RB, Beiser M, Bean G) 164

**health care service use**

Long-term medical conditions and major depression in the Canadian population (Patten SB) 151

**hemodialysis**

Clinical ratings of compliance in hemodialysis patients (Mai FM, Busby K, Bell RC) 478

**Holocaust survivors, children of**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34



**hospital days**

Hospital days in risperidone-treated patients (Dickson RA, Dalby JT, Adding-ton D, Williams R, McDougall GM) 909

**hospital-discharge data**

Validity of hospital-discharge data [letter] (Patten SB) 189

**hospitalization**

Is hospitalization bad for patients with psychiatric problems? [letter] (O'Reilly RL) 709

**hospital outcome measures**

Hospital outcome measures following assertive community treatment in Ed-monton, Alberta (Tibbo P, Chue P, Wright E) 276

**human-capital approach**

The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia (Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P) 455

**hyperactivity**

The treatment of attention-deficit hyperactivity disorder: an annotated bibli-ography and critical appraisal of published systematic reviews and metaanal-yses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025

**hypercortisolemia**

Hypercortisolemia and post-ECT confusion [letter] (Kiraly SJ, Ancill RJ, Jur-alowicz P, Kroeker G) 92

**hyperesthesia**

Creativity, hyperesthesia, and mental illness [letter] (Gordon AG) 91

**hypnosis**

The effects of hypnosis on dissociative identity disorder: a reexamination of the evidence (Powell RA, Gee TL) 914

**I****iatrogenesis**

The effects of hypnosis on dissociative identity disorder: a reexamination of the evidence (Powell RA, Gee TL) 914

**identifying future psychiatrists**

Recruitment into psychiatry: increasing the pool of applicants (Weintraub W, Plaut SM, Weintraub E) 473

**imaging**

Imaging of autism: lessons from the past to guide studies in the future (Gold-berg J, Szatmari P, Nahmias C) 793

**implantation**

L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé (Benoit F, Lesage AD) 781

**impulse**

Lamotrogine and impulse behaviour [letter] (Daly KA, Fatemi SH) 395

**increasing the pool of applicants**

Recruitment into psychiatry: increasing the pool of applicants (Weintraub W, Plaut SM, Weintraub E) 473

**indirect cost**

The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia (Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P) 455

**individual treatment outcome**

A comparison of short-term group and individual therapy for sexually abused women (Stalker CA, Fry R) 168

**informant**

Identification of childhood psychiatric disorder by informant: comparisons of clinic and community samples (MacLeod RJ, McNamee JE, Boyle MH, Of-ford DR, Friedrich M) 144

**injury prevention**

Suicide in the Montreal subway system: characteristics of the victims, antece-dents, and implications for prevention (Mishara BL) 690

**interpersonal psychotherapy**

Developments in interpersonal psychotherapy (Markowitz JC) 556

**involuntary certification**

Review Board outcomes for involuntary patients in provincial psychiatric hospitals (Komer WJ, O'Reilly RL, Cernovsky Z, Dunbar S) 495

**L****lamotrogine**

Lamotrogine and impulse behaviour [letter] (Daly KA, Fatemi SH) 395

**late paraphrenia**

Paraphrenia redefined (Ravindran AV, Yatham LN, Munro A) 133

**legislation**

Re: mental health legislation and the right to appropriate treatment [letter] (Cadotte B) 504; [response] (O'Reilly R) 505

Re: mental health legislation and the right to appropriate treatment [letter] (Gray JE, Keegan D) 394; [response] (O'Reilly R) 503

**Lehmann H**

Heinz Lehmann: a pioneer of modern psychiatry [in memoriam] (Paris J) 441

**lesions**

Implications of lesion-clinical correlation in poststroke depression [letter] (Ramasubbu R) 506

**life skills**

Complementary development of prevention and mental health promotion pro-grams for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

**lithium**

Séquelles neurologiques secondaires à une intoxication aiguë au lithium (Roy M, Stip E, Black DN, Lew V, Langlois R) 671

**living arrangements**

Living arrangement requirements for individuals with developmental disabil-ity and behavioural problems (Fotheringham JB) 589

**loi**

Refus catégorique de traitement des patients psychiatriques : bilan, enquête et perspective (Trudeau M-H, Bruneau M-A, Stip E, Grünberg F, Boivin M) 583

**M****magnetic resonance imaging**

Imaging of autism: lessons from the past to guide studies in the future (Gold-berg J, Szatmari P, Nahmias C) 793

**male**

A comparison of male and female adolescents referred to an eating disorder program (Geist R, Heinmaa M, Katzman D, Stephens D) 374

**management**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017

**mania**

Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

Mania and donepezil [letter] (Benazzi F, Rossi E) 506

Olanzapine-induced psychotic mania in bipolar schizoaffective disorder [let-ter] (Benazzi F) 607

**measurement**

Identification of childhood psychiatric disorder by informant: comparisons of clinic and community samples (MacLeod RJ, McNamee JE, Boyle MH, Of-ford DR, Friedrich M) 144

**medical education**

Curriculum renewal in child psychiatry (Hanson M, Tiberius R, Charach A, Ulzen T, Sackin D, Jain U, Reiter S, Shomair G) 874

**medical school**

Recruitment into psychiatry: increasing the pool of applicants (Weintraub W, Plaut SM, Weintraub E) 473

**medication**

Cognitive-behaviour therapy and medication in the treatment of obses-sive-compulsive disorder: a controlled study (O'Connor K, Todorov C, Ro-billard S, Borgeat F, Brault M) 64

**medication management**

The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? (Pelham WE Jr) 981

**Mental Health Act**

Review Board outcomes for involuntary patients in provincial psychiatric hospitals (Komer WJ, O'Reilly RL, Cernovsky Z, Dunbar S) 495

Why are patients discharged by Review Boards? (O'Reilly RL, Komer W, Dunbar S) 259

**mental health promotion**

Complementary development of prevention and mental health promotion pro-grams for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

Does regular attendance at sporting events promote mental health? [letter] (Hintikka J, Viinamäki H, Koskela K, Kontula O) 608

- Mentally healthier Canadians [editorial] (Lesage A) 226
- mental retardation**  
Abnormal involuntary movements in neuroleptic-naïve children and adolescents (Magulac M, Landsverk J, Golshan S, Jeste DV) 368  
Living arrangement requirements for individuals with developmental disability and behavioural problems (Fotheringham JB) 589  
Psychiatric aspects of sexual abuse involving persons with developmental disabilities (McCreary BD, Thompson J) 350
- metaanalysis**  
Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies (Klassen A, Miller A, Raina P, Lee SK, Olsen L) 1007  
The treatment of attention deficit-hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025
- methylphenidate**  
In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder (Cunningham CE) 999  
Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Glor K, Dunn J) 680
- metro**  
Suicide in the Montreal subway system: characteristics of the victims, antecedents, and implications for prevention (Mishara BL) 690
- millennium**  
Millennium—fantasy, furor, and fact [editorial] (Rae-Grant Q) 18  
Re: editorial I—millennium—fantasy, furor, and fact [letter] (Pakes EH) 708
- Millon Clinical Multiaxial Inventory**  
Prevalence of personality disorders among clients in treatment for addiction (Nadeau L, Landry M, Racine S) 592
- minor physical abnormalities**  
Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335
- moclobemide**  
Moclobemide response in obsessive-compulsive disorder [letter] (Al Jeshi A) 285
- mood-congruent psychosis**  
Psychotic side effects of psychostimulants: a review of 5 years of practice (Cherland E, Fitzpatrick R) 811
- movement disorder**  
Abnormal involuntary movements in neuroleptic-naïve children and adolescents (Magulac M, Landsverk J, Golshan S, Jeste DV) 368
- multimodal treatment**  
Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975
- N**
- nail-biting**  
Cessation of nail-biting and bupropion [letter] (Wadden P, Pawliuk G) 709  
The self-mutilative nature of severe onychophagia: a comparison with self-cutting (Wells JH, Haines J, Williams CL, Brain KL) 40
- narcolepsy**  
Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Glor K, Dunn J) 680
- nefazodone**  
Nefazodone-induced visual disturbances [letter] (Mosherian P, Leung M, Hollander Y, Remick RA) 925  
Nefazodone withdrawal syndrome [letter] (Lauber C) 285  
Re: nefazodone withdrawal symptoms [letter] (Markowitz JS) 286; [response] (Benazzi F) 287
- neurobiology**  
Neurobiology of early antecedents of adult health problems [letter] (Friedman EH) 1053  
Neurobiology of the immune system and infection in the effects of psychological factors on the cardiovascular system [letter] (Friedman E) 284
- neurodevelopment**  
Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335
- neuroleptic malignant syndrome**  
Atypical neuroleptic malignant syndrome [letter] (Haggarty JM, Husni M, Peat C, Allain S) 711
- neuroleptics**  
A comparative review of new antipsychotics (Blin O) 235

## neurological side effects

- Séquelles neurologiques secondaires à une intoxication aiguë au lithium (Roy M, Stip E, Black DN, Lew V, Langlois R) 671

## neurological soft signs

- Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335

## neuropsychological

- A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775

## nicotine

- An attempted suicide using transdermal nicotine patches [letter] (Labelle A, Boulay LJ) 190

## nifedipine

- Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

## O

## observance

- Refus catégorique de traitement des patients psychiatriques: bilan, enquête et perspective (Trudeau M-H, Bruneau M-A, Stip E, Grünberg F, Boivin M) 583

## obsessive-compulsive disorder

- Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive-compulsive disorder (Stephens RJ, Sandor P) 1036

- Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study (O'Connor K, Todorov C, Robillard S, Borgeat F, Brault M) 64

- Computer aids to mental health care (I Marks) 548

- Level of schooling and obsessive-compulsive disorder [letter] (Petrubá K, Bastos O, de Oliveira IR) 93

- Moclobemide response in obsessive-compulsive disorder [letter] (Al Jeshi A) 285

- Obsessive-compulsive spectrum disorders: effective treatment with paroxetine (Ravindran AV, Lapiere YD, Anisman H) 805

- Polyglandular autoimmune syndrome type II and paranoid schizophrenia with obsessive-compulsive disorder [letter] (Asghar SJ, Chue PS, Coupland NJ, Tibbo P) 391

## obsessive-compulsive spectrum disorders

- Obsessive-compulsive spectrum disorders: effective treatment with paroxetine (Ravindran AV, Lapiere YD, Anisman H) 805

## olanzapine

- Is olanzapine a mood stabilizer? [letter] (Ananth J) 927

- A new mechanism for the actions of olanzapine [letter] (Li X-M, Juorio AV, Chlan-Fourney J, Shrikhande S, Bennett VL, Keegan DL) 605

- Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study (Dursun SM, Gardner DM, Bird DC, Flinn J) 701

- Olanzapine in an intensive care unit [letter] (Anand HS) 397

- Olanzapine-induced psychotic mania in bipolar schizoaffective disorder [letter] (Benazzi F) 607

- Tardive dyskinesia from risperidone and olanzapine in an alcoholic man [letter] (Snoddgrass PL, Labbate LA) 921

## Ontario

- Child psychiatry practice patterns in Ontario (Steele MM, Veitch Wolfe V) 788

## onychophagia

- The self-mutilative nature of severe onychophagia: a comparison with self-cutting (Wells JH, Haines J, Williams CL, Brain KL) 40

## organisation des soins de santé

- L'implantation du suivi intensif dans la communauté: des leçons à tirer du passé (Benoit F, Lesage AD) 781

## organismes communautaires

- Évaluation du potentiel de ressources communautaires en santé mentale (Walton H) 48

## outcome

- Clinical predictors of short-term outcome in electroconvulsive therapy (Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP) 158

- Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975

- Hospital days in risperidone-treated patients (Dickson RA, Dalby JT, Adding-ton D, Williams R, McDougall GM) 909

**outcome evaluation**

Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity (el-Guebaly N, Hodgins DC, Armstrong S, Addington J) 264

**P****PACT (Program for Assertive Community Treatment)**

L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé (Benoit F, Lesage AD) 781

**panic**

Computer aids to mental health care (I Marks) 548

**panic attacks**

Panic disorder in schizophrenia (Labbate LA, Christopherson Young P, Arana GW) 488

**panic disorder**

Panic disorder in schizophrenia (Labbate LA, Christopherson Young P, Arana GW) 488

**paradigm**

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

**paranoid schizophrenia**

Paraphrenia redefined (Ravindran AV, Yatham LN, Munro A) 133  
Polyglandular autoimmune syndrome type II and paranoid schizophrenia with obsessive-compulsive disorder [letter] (Asghar SJ, Chue PS, Coupland NJ, Tibbo P) 391

**paraphrenia**

Paraphrenia redefined (Ravindran AV, Yatham LN, Munro A) 133

**parent training**

In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder (Cunningham CE) 999

**paroxetine**

Obsessive-compulsive spectrum disorders: effective treatment with paroxetine (Ravindran AV, Lapiere YD, Anisman H) 805

**partenariat**

Évaluation du potentiel de ressources communautaires en santé mentale (Walot H) 48

**paternal filicide**

Paternal filicide: a study of 10 men (Marleau JD, Poulin B, Webanck T, Roy R, Laporte L) 57

**pathological gambling**

Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire (Beaudoin CM, Cox BJ) 483  
Prevalence of problem gambling: a replication study seven years later (Ladouceur R, Jacques C, Ferland F, Giroux I) 802

**patients**

Paternal filicide: a study of 10 men (Marleau JD, Poulin B, Webanck T, Roy R, Laporte L) 57

**pemoline**

Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Gior K, Dunn J) 680

**père**

Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection (Vitaro F, Tremblay RE, Zoccolillo M) 901

**personality**

A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775

**personality disorder**

Prevalence of personality disorders among clients in treatment for addiction (Nadeau L, Landry M, Racine S) 592

**personality preservation**

Paraphrenia redefined (Ravindran AV, Yatham LN, Munro A) 133

**phobias**

Computer aids to mental health care (I Marks) 548

**physician**

A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775

**physician practice patterns**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017

**placebo control**

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapiere YD) 887

**polyglandular autoimmune syndrome**

Polyglandular autoimmune syndrome type II and paranoid schizophrenia with obsessive-compulsive disorder [letter] (Asghar SJ, Chue PS, Coupland NJ, Tibbo P) 391

**population survey**

Mental health service use: a comparison of treated and untreated individuals with substance-use disorders in Ontario (Ross HE, Lin E, Cunningham J) 570

**Positive and Negative Syndrome Scale**

An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale (Lançon C, Aghababian V, Llorca PM, Bernard D, Auquier P) 893

**postmodernism**

Psychoanalytic contributions to the study of gender issues (Barbieri NB) 72

**poststroke depression**

Implications of lesion-clinical correlation in poststroke depression [letter] (Ramassubbu R) 506

**posttraumatic distress**

Re: individual differences in posttraumatic distress [letter] (Grauer H) 708

**posttraumatic stress disorder**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

Does stress cause posttraumatic stress disorder? [editorial] (Paris J) 20

Individual differences in posttraumatic distress: problems with the DSM-IV model (Bowman ML) 21

Re: posttraumatic stress disorder [letter] (Shatan CF) 817; [response] (Paris J) 817

Re: posttraumatic stress disorder and exposure [letter] (Sigal J) 817; [response] (Paris J) 818

Validation of a French version of the Dissociative Experiences Scale in a rape-victim population (Darves-Bornoz J-M, Degiovanni A, Gaillard P) 271

**practice patterns**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017

Child psychiatry practice patterns in Ontario (Steele MM, Veitch Wolfe V) 788

**precursors**

Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335

**predictors**

Clinical predictors of short-term outcome in electroconvulsive therapy (Lam RW, Bartley S, Yatham LN, Tam EM, Zis AP) 158

**pregnancy**

Prenatal factors and adult mental and physical health (Susser EB, Brown A, Matte TD) 326

**prenatal exposure**

Prenatal factors and adult mental and physical health (Susser EB, Brown A, Matte TD) 326

**prevalence**

Prevalence of problem gambling: a replication study seven years later (Ladouceur R, Jacques C, Ferland F, Giroux I) 802

**prevention**

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

Conduct disorder: practice parameters for assessment, treatment, and prevention (Waddell C, Lipman E, Offord D) 355

Suicide in the Montreal subway system: characteristics of the victims, antecedents, and implications for prevention (Mishara BL) 690

**prévention primaire**

Comment prévenir l'apparition d'un trouble de stress post-traumatique avant un traumatisme ? (Melançon G, Boyer R) 253

**primary health care**

The impact of primary mental health care in a prison system in Brazil (Taborda JGV, Bertolote JM, Cardoso RG, Blank P) 180

**principal-component analysis**

An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale (Lançon C, Aghababian V, Llorca PM, Bernard D, Auquier P) 893

**prison hospital**

The impact of primary mental health care in a prison system in Brazil (Taborda JGV, Bertolote JM, Cardoso RG, Blank P) 180

**problem gambling**

Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire (Beaudoin CM, Cox BJ) 483

**productivity cost**

The economic burden of schizophrenia in Canada (Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J) 464

The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia (Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P) 455

**protective factors**

Risk and Protective Factors Scale: reliability and validity in preadolescents (Looper K, Grizenko N) 138

**psychiatric resident training**

Psychiatric residents' views on their training and experience regarding issues related to child abuse (Barnard-Thompson K, Lechner P) 769

**psychiatrie légale**

Refus catégorique de traitement des patients psychiatriques : bilan, enquête et perspective (Trudeau M-H, Bruneau M-A, Stip E, Grünberg F, Boivin M) 583

**psychiatrists**

Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Glor K, Dunn J) 680

**psychoanalysis**

Psychoanalytic contributions to the study of gender issues (Barbieri NB) 72

**psychopathology**

Prevalence of DSM-IV disorders in children and adolescents with asthma versus diabetes (Vila G, Nollet-Clemençon C, Vera M, Robert JJ, de Blic J, Jouvencé R, Mouren-Simeoni MC, Scheinmann P) 562

**psychose**

Refus catégorique de traitement des patients psychiatriques : bilan, enquête et perspective (Trudeau M-H, Bruneau M-A, Stip E, Grünberg F, Boivin M) 583

**psychosis**

Abnormal involuntary movements in neuroleptic-naïve children and adolescents (Magulac M, Landsverk J, Golshan S, Jeste DV) 368

Cognitive-behavioural therapy for psychosis: a status report (Norman RMG, Townsend LA) 245

Exploring the longitudinal course of psychotic illness: a case-study approach (Cortese L, Malla AK, McLean T, Diaz JF) 881

Panic disorder in schizophrenia (Labbate LA, Christopherson Young P, Arana GW) 488

Psychotic side effects of psychostimulants: a review of 5 years of practice (Cherland E, Fitzpatrick R) 811

**psychosocial factors**

Emotional adaptation of children undergoing bone marrow transplantation (Günter M, Karle M, Werning A, Klingebiel T) 77

**psychostimulants**

A rapid response with psychostimulants in the treatment of depressed persons with medical illnesses [letter] (Roy M, Bernier J) 283

Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Glor K, Dunn J) 680

**psychotherapy**

Developments in interpersonal psychotherapy (Markowitz JC) 556

Guidelines for the psychotherapies in comprehensive psychiatric care: a discussion paper (Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2) 45

The practice and roles of the psychotherapies: a discussion paper (Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1) 185

Psychotherapies and the practice of psychiatry (Canadian Psychiatric Association Psychotherapies Steering Committee Chair) 35

Strengthening the psychotherapies [editorial] (Cameron PM) 547

**pulmonary embolus**

Pulmonary embolus possibly associated with clozapine treatment [letter] (Lalica S, Cooper JP) 396

**Q****quantitative systematic review**

Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies (Klassen A, Miller A, Raina P, Lee SK, Olsen L) 1007

**quetiapine**

Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? [letter] (Stip E, Bojsjoly H) 503

**R****randomized clinical trials**

Developments in interpersonal psychotherapy (Markowitz JC) 556

**rape**

Validation of a French version of the Dissociative Experiences Scale in a rape-victim population (Darves-Bornoz J-M, Degiovanni A, Gaillard P) 271

**rating scale**

Clinical ratings of compliance in hemodialysis patients (Mai FM, Busby K, Bell RC) 478

**recherche sur les services**

L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé (Benoit F, Lesage AD) 781

**recruitment**

Recruitment into psychiatry: increasing the pool of applicants (Weintraub W, Plaut SM, Weintraub E) 473

**reduplicative paramnesia**

Bilateral anterior cortical atrophy and subcortical atrophy in reduplicative paramnesia: a case-control study of computed tomography in 10 patients (Joseph AB, O'Leary DH, Kurland R, Ellis HD) 685

**relative age**

A new factor in youth suicide: the relative age effect (Thompson AH, Barnsley RH, Dyck RJ) 82

**reliability**

An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale (Lançon C, Aghababian V, Llorca PM, Bernard D, Auquier P) 893

**remuneration**

Child psychiatry practice patterns in Ontario (Steele MM, Veitch Wolfe V) 788

**research**

Is it time for a Canadian institute of mental illness and mental health research? [letter] (Canadian Psychiatric Association Scientific and Research Council: Addington D, Enns M, Moamai J, Morehouse R, Porter A, Shrikande S, Styra R, Yatham L) 1049

**residency**

Recruitment into psychiatry: increasing the pool of applicants (Weintraub W, Plaut SM, Weintraub E) 473

**resilience**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

**résilience**

Père alcoolique, consommation de psychotropes à l'adolescence et facteurs de protection (Vitaro F, Tremblay RE, Zoccolillo M) 901

**responsibility**

Who will protect mentally ill individuals from themselves? [letter] (Melamed Y, Lublinsky E, Mazeh D) 393

**restrictive measures**

Restrictive measures in a psychiatric hospital on weekdays versus on weekends or holidays [letter] (Jin C, Sher L) 505

**retention rates**

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapierre YD) 887

**retrospective**

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapierre YD) 887

**review**

Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies (Klassen A, Miller A, Raina P, Lee SK, Olsen L) 1007

**Review Boards**

Review Board outcomes for involuntary patients in provincial psychiatric hospitals (Komer WJ, O'Reilly RL, Cernovsky Z, Dunbar S) 495

Why are patients discharged by Review Boards? (O'Reilly RL, Komer W, Dunbar S) 259

**revoked certificate**

Why are patients discharged by Review Boards? (O'Reilly RL, Komer W, Dunbar S) 259

**rights**

Re: mental health legislation and the right to appropriate treatment [letter] (Cadotte B) 504; [response] (O'Reilly R) 505

Re: mental health legislation and the right to appropriate treatment [letter] (Gray JE, Keegan D) 394; [response] (O'Reilly R) 503



**risk factors**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

Risk and Protective Factors Scale: reliability and validity in preadolescents (Looper K, Grizenko N) 138

**risperidone**

Hospital days in risperidone-treated patients (Dickson RA, Dalby JT, Addington D, Williams R, McDougall GM) 909

Risperidone as an adjunct to valproic acid [letter] (Waring EW, Dewan VK, Cohen D, Grewal R) 189

Tardive dyskinesia from risperidone and olanzapine in an alcoholic man [letter] (Snoddgrass PL, Labbate LA) 921

Tardive dystonia induced by risperidone [letter] (Krebs MO, Olie JP) 507

**rôle**

Évaluation du potentiel de ressources communautaires en santé mentale (Wal-lot H) 48

**S****santé mentale**

Évaluation du potentiel de ressources communautaires en santé mentale (Wal-lot H) 48

**scale**

Risk and Protective Factors Scale: reliability and validity in preadolescents (Looper K, Grizenko N) 138

**schizophrenia**

Attributional style and depression in schizophrenia (Addington D, Addington J, Robinson G) 697

Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

Cognitive-behavioural therapy for psychosis: a status report (Norman RMG, Townsend LA) 245

A comparative review of new antipsychotics (Blin O) 235

The economic burden of schizophrenia in Canada (Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J) 464

Feasibility of client reports to measure treatment outcome in schizophrenia [letter] (Baigent L, Ostbye T, MLD Fernando) 94

Group treatment of substance abuse for patients with schizophrenia or related disorders [letter] (Cohen D, Tempier R) 928

Hospital days in risperidone-treated patients (Dickson RA, Dalby JT, Addington D, Williams R, McDougall GM) 909

Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia [letter] (Tibbo P, Gendemann K) 1050

Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study (Dursun SM, Gardner DM, Bird DC, Flinn J) 701

Panic disorder in schizophrenia (Labbate LA, Christopherson Young P, Arana GW) 488

Precursors to schizophrenia [editorial] (Bland RC) 325

Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335

Prenatal factors and adult mental and physical health (Susser EB, Brown A, Matte TD) 326

Re: Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia [letter] (Haslam DRS, Gardner DM, Oluboka T) 390; [response] (Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia: Addington D, Bassett AS, Cook P, Dickson R, Goldberg J, Honer B, Kopala L, Malla A) 391

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapierre YD) 887

Treatment of schizophrenia with antipsychotics in combination [letter] (Waring EW, Devin PG, Dewan V) 189

The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia (Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P) 455

**school**

A new factor in youth suicide: the relative age effect (Thompson AH, Barnsley RH, Dyck RJ) 82

**schooling**

Level of schooling and obsessive-compulsive disorder [letter] (Petribù K, Bastos O, de Oliveira IR) 93

**seizure**

Clozapine does not increase ECT-seizure duration [letter] (Husni M, Haggarty J, Peat C) 190

Factors influencing ratio of motor and EEG seizure duration in ECT [letter] (Mayur PM, Gangadhar BN, Janakiramaiah N) 191

**scientific paradigms**

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms (Breton JJ) 227

**selective serotonin reuptake inhibitor**

Citalopram: a rapid onset selective serotonin reuptake inhibitor? [letter] (Crow S, Daly KA, Fatemi SH, MacGraw R, Meller W) 1052

Obsessive-compulsive spectrum disorders: effective treatment with paroxetine (Ravindran AV, Lapierre YD, Anisman H) 805

Re: selective serotonin reuptake inhibitor discontinuation syndrome: putative mechanisms and prevention strategies [letter] (Benazzi F) 95

**self-treatment**

Computer aids to mental health care (I Marks) 548

**serotonin**

A comparative review of new antipsychotics (Blin O) 235

**service costs**

Economic impacts of assertive community treatment: a review of the literature (Latimer EA) 443

**service use**

Mental health service use: a comparison of treated and untreated individuals with substance-use disorders in Ontario (Ross HE, Lin E, Cunningham J) 570

**sex offender**

A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775

**sexual abuse**

Psychiatric aspects of sexual abuse involving persons with developmental disabilities (McCreary BD, Thompson J) 350

**sexual disorder**

A study of physicians who commit sexual offences (Langevin R, Glancy G, Curnoe S, Bain J) 775

**sexual dysfunction**

Antidepressants and sexual dysfunction [letter] (McIntyre RS) 926

**sexual recidivism**

Re: sexual recidivism in sex offenders [letter] (Cooper AJ) 94

**sexually abused women**

A comparison of short-term group and individual therapy for sexually abused women (Stalker CA, Fry R) 168

**short-term therapy**

A comparison of short-term group and individual therapy for sexually abused women (Stalker CA, Fry R) 168

**side effects**

Psychotic side effects of psychostimulants: a review of 5 years of practice (Cherland E, Fitzpatrick R) 811

**skin-cutting**

The self-mutilative nature of severe onychophagia: a comparison with self-cutting (Wells JH, Haines J, Williams CL, Brain KL) 40

**smoking**

Computer aids to mental health care (I Marks) 548

Level of activity and prevalence of smoking in psychiatric patients [letter] (Challis GB) 711

**solutions de rechange à l'hospitalisation**

L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé (Benoit F, Lesage AD) 781

**specificity**

Attributional style and depression in schizophrenia (Addington D, Addington J, Robinson G) 697

Precursors to schizophrenia: do biological markers have specificity? (Tarrant CJ, Jones PB) 335

**sports**

Does regular attendance at sporting events promote mental health? [letter] (Hintikka J, Viinämäki H, Koskela K, Kontula O) 608

**statistics**

Confronting the confounders: the meaning, detection, and treatment of confounders in research (Rhodes AE, Lin E, Streiner DL) 175



**stimulants**

Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives (Miller A) 1017

In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder (Cunningham CE) 999

Lessons from large trials: the MTA Study as a model for evaluating the treatment of childhood psychiatric disorder (Boyle MH, Jadad AR) 991

Psychotic side effects of psychostimulants: a review of 5 years of practice (Cherland E, Fitzpatrick R) 811

The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025

**stressful life events**

Individual differences in posttraumatic distress: problems with the DSM-IV model (Bowman ML) 21

**stress reactions**

Emotional adaptation of children undergoing bone marrow transplantation (Günter M, Karle M, Werning A, Klingebiel T) 77

**study design**

The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? (Pelham WE Jr) 981

**substance abuse**

Group treatment of substance abuse for patients with schizophrenia or related disorders [letter] (Cohen D, Tempier R) 928

**substance disorder**

Mental health service use: a comparison of treated and untreated individuals with substance-use disorders in Ontario (Ross HE, Lin E, Cunningham J) 570

Prevalence of personality disorders among clients in treatment for addiction (Nadeau L, Landry M, Racine S) 592

**substance-related comorbidity**

Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity (el-Guebaly N, Hodgins DC, Armstrong S, Addington J) 264

**substance-related disorders**

Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity (el-Guebaly N, Hodgins DC, Armstrong S, Addington J) 264

**subway**

Suicide in the Montreal subway system: characteristics of the victims, antecedents, and implications for prevention (Mishara BL) 690

**suicidal behaviour**

Relationship between attachment-felt security and history of suicidal behaviours in clinical adolescents (West ML, Spreng SW, Rose SM, Adam KS) 578

**suicide**

An attempted suicide using transdermal nicotine patches [letter] (Labelle LA, Boulay LJ) 190

Elderly suicide in Alberta: difference by gender (Quan H, Arboleda-Florez J) 762

A new factor in youth suicide: the relative age effect (Thompson AH, Barnsley RH, Dyck RJ) 82

Suicide in the Montreal subway system: characteristics of the victims, antecedents, and implications for prevention (Mishara BL) 690

**suivie intensif dans la communauté**

L'implantation du suivi intensif dans la communauté : des leçons à tirer du passé (Benoit F, Lesage AD) 781

**survey**

Child psychiatry practice patterns in Ontario (Steele MM, Veitch Wolfe V) 788

Identification of childhood psychiatric disorder by informant: comparisons of clinic and community samples (MacLeod RJ, McNamee JE, Boyle MH, Offord DR, Friedrich M) 144

Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey (Beck C, Silverstone P, Gior K, Dunn J) 680

**survival analysis**

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia (Labelle A, Boulay LJ, Lapierre YD) 887

The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025

**T****tardive dyskinesia**

Abnormal involuntary movements in neuroleptic-naïve children and adolescents (Magulac M, Landsverk J, Golshan S, Jeste DV) 368

Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

Tardive dyskinesia from risperidone and olanzapine in an alcoholic man [letter] (Snodgrass PL, Labbate LA) 921

**tardive dystonia**

Tardive dystonia induced by risperidone [letter] (Krebs MO, Olie JP) 507

**teachers**

Graduating teachers' knowledge and attitudes about attention-deficit hyperactivity disorder: a comparison with practicing teachers [letter] (Jerome L, Washington P, Laine CJ, Segal A) 192

**tension reduction**

The self-mutilative nature of severe onychophagia: a comparison with self-cutting (Wells JH, Haines J, Williams CL, Brain KL) 40

**therapy**

A comparison of short-term group and individual therapy for sexually abused women (Stalker CA, Fry R) 168

**tolérance au traitement**

Des variations intersexuelles relatives aux traitements en psychiatrie (Godfroid IO) 362

**tomography, emission computed**

Imaging of autism: lessons from the past to guide studies in the future (Goldberg J, Szatmari P, Nahmias C) 793

**Tourette syndrome**

Aggressive behaviour in children with Tourette syndrome and comorbid attention-deficit hyperactivity disorder and obsessive-compulsive disorder (Stephens RJ, Sandor P) 1036

Cyproterone acetate treatment of Tourette's syndrome [letter] (Izmir M, Duran SM) 710

**toxicity**

Séquelles neurologiques secondaires à une intoxication aiguë au lithium (Roy M, Stip E, Black DN, Lev V, Langlois R) 671

**train**

Suicide in the Montreal subway system: characteristics of the victims, antecedents, and implications for prevention (Mishara BL) 690

**training**

Psychiatric residents' views on their training and experience regarding issues related to child abuse (Barnard-Thompson K, Lechner P) 769

**traitement**

Refus catégorique de traitement des patients psychiatriques : bilan, enquête et perspective (Trudeau M-H, Bruneau M-A, Stip E, Grünberg F, Boivin M) 583

**treatment**

Conduct disorder: practice parameters for assessment, treatment, and prevention (Waddell C, Lipman E, Offord D) 355

Fact versus fancy concerning the multimodal treatment study for attention-deficit hyperactivity disorder (Jensen PS) 975

Guidelines for the psychotherapies in comprehensive psychiatric care: a discussion paper (Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 2) 45

The practice and roles of the psychotherapies: a discussion paper (Canadian Psychiatric Association Psychotherapies Steering Committee Working Group 1) 185

Prevalence of personality disorders among clients in treatment for addiction (Nadeau L, Landry M, Racine S) 592

Psychotherapies and the practice of psychiatry (Canadian Psychiatric Association Psychotherapies Steering Committee Chair) 35

The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses (Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R) 1025

**treatment acceptability**

Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month treatment trial (Corkum P, Rimer P, Schachar R) 1043

**treatment adherence**

Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month treatment trial (Corkum P, Rimer P, Schachar R) 1043

**treatment difficulties**

Difficulties in treating patients with eating disorders: a review of patient and clinician variables (Kaplan AS, Garfinkel PE) 665

**treatment-resistant schizophrenia**

Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study (Dursun SM, Gardner DM, Bird DC, Flinn J) 701

**trouble de stress post-traumatique**

Comment prévenir l'apparition d'un trouble de stress post-traumatique avant un traumatisme ? (Mélancçon G, Boyer R) 253

**U****undergraduate medical education**

Curriculum renewal in child psychiatry (Hanson M, Tiberius R, Charach A, Ulzen T, Sackin D, Jain U, Reiter S, Shomair G) 874

**uremia**

Valproic acid intoxication in a patient with bipolar disorder and chronic uremia [letter] (Lapierre O, Dubreucq J-L, Beauchemin M-A, Vinet B) 188

**V****validation**

Validation of a French version of the Dissociative Experiences Scale in a rape-victim population (Darves-Bornoz J-M, Degiovanni A, Gaillard P) 271

**validity**

An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale (Lançon C, Aghababian V, Llorca PM, Bernard D, Auquier P) 893

Validity of hospital-discharge data [letter] (Patten SB) 189

**valproic acid**

Risperidone as an adjunct to valproic acid [letter] (Waring EW, Dewan VK, Cohen D, Grewal R) 189

Valproic acid intoxication in a patient with bipolar disorder and chronic uremia [letter] (Lapierre O, Dubreucq J-L, Beauchemin M-A, Vinet B) 188

**venlafaxine**

Abnormal clotting and production of factor VIII inhibitor in a patient treated with venlafaxine [letter] (Tham CJ, Trew M, Brager N) 923

**verapamil**

Calcium channel blockers in psychiatric disorders: a review of the literature (Hollister LE, Garza Trevino ES) 658

**visual disturbances**

Nefazodone-induced visual disturbances [letter] (Mosberian P, Leung M, Hollander Y, Remick RA) 925

**vulnerability**

Biological factors associated with susceptibility to posttraumatic stress disorder (Yehuda R) 34

**Y****youth**

A new factor in youth suicide: the relative age effect (Thompson AH, Barnsley RH, Dyck RJ) 82

## Special Articles

**In Memoriam**

Heinz Lehmann: a pioneer of modern psychiatry (Paris J) 441

Naomi Ingrid Rae-Grant (Davidson S) 973

**Presidential Address**

Pioneering aspects of psychiatry (el-Guebaly N) 868

**Supplement**

Conduct disorder: practice parameters for assessment, treatment, and prevention (Waddell C, Lipman E, Offord D) 33S-40S

Psychotherapies and the practice of psychiatry (Working Groups 1 and 2 of the Canadian Psychiatric Association Psychotherapies Steering Committee) 1S-32S

